<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12093676</article-id><article-id pub-id-type="publisher-id">3463</article-id><article-id pub-id-type="doi">10.1186/s12974-025-03463-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>RiboTag-based RNA profiling uncovers oligodendroglial lineage-specific inflammation in autoimmune encephalomyelitis: implications for pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yuhang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ghimire</surname><given-names>Sudeep</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mangalam</surname><given-names>Ashutosh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kang</surname><given-names>Zizhen</given-names></name><address><email>zizhen-kang@uiowa.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036jqmy94</institution-id><institution-id institution-id-type="GRID">grid.214572.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8294</institution-id><institution>Department of Pathology, </institution><institution>University of Iowa, </institution></institution-wrap>Iowa City, IA 52242 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><elocation-id>135</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Oligodendroglial lineage cells (OLCs) are essential for myelination, remyelination and neuronal metabolic support, but recent evidence suggests they also play active roles in neuroinflammation. This study aimed to identify the inflammatory translatome of OLCs during the onset of experimental autoimmune encephalomyelitis (EAE), a widely used model for Multiple Sclerosis (MS), using RiboTag-based RNA sequencing. We crossed RiboTag mice with Olig2-Cre mice to obtain strain-specific expression of HA-tagged ribosomal protein Rpl22 in OLCs, enabling the isolation of ribosome-associated mRNA from these cells for sequencing by using HA beads. Compared to controls, 1,556 genes were upregulated and 683 were downregulated in EAE OLCs. Gene enrichment revealed elevated immune-related pathways, including cytokine signaling, interferon responses and antigen presentation, whereas downregulated genes were associated with myelination and neuronal development. Notably, significant expression of cytokines/chemokines and their receptors was detected in OLCs. Further investigations focused on the role of IFNGR and IFNAR in EAE pathogenesis. IFN-&#x003b3; signaling in OLCs exacerbated EAE pathogenesis by enhancing antigen processing, presentation, and chemokine production (e.g., Ccl2, Ccl7). In contrast, IFN-&#x003b2; signaling appeared less critical. These findings highlight the inflammatory role of OLCs in EAE, suggesting OLCs as a potential therapeutic target for mitigating neuroinflammation in MS and related disorders.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12974-025-03463-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oligodendroglial lineage cells</kwd><kwd>Autoimmune encephalomyelitis</kwd><kwd>Multiple sclerosis</kwd><kwd>RiboTag RNA-seq</kwd></kwd-group><funding-group><award-group><funding-source><institution>NIH</institution></funding-source><award-id>T32AI007260</award-id><award-id>NIH R01 NS104164</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">OPCs constitute the fourth largest population of glial cells within the central nervous system (CNS), accounting for approximately 5% of all CNS cells and enduring from infancy into adulthood [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Remarkably, OPCs exhibit an even distribution throughout the CNS, lacking specific niches and distinguishing themselves from transient cell populations typical of other progenitor cells. Traditionally recognized for their role in generating mOLs responsible for axon myelination in the spinal cord and brain, OPCs originate from radial glia in ventricular zones during embryonic development. Subsequently, they undergo local proliferation, migration, and differentiation into mOLs during both development and following injury [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Given their persistent presence across the CNS, it has been hypothesized that OPCs may serve functions beyond mere precursor roles over extended periods. Indeed, emerging research has collectively revealed myelination-independent functions of OPCs in both health and disease contexts, including involvement in inflammatory responses, neural circuitry remodeling, axon regeneration, angiogenesis, and neuronal development [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par3">MS is an autoimmune demyelinating disorder impacting 2&#x02013;3&#x000a0;million individuals worldwide, with a prevalence ranging from 50 to 300 per 100,000 people [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Although the exact mechanisms remain elusive, it is well-established that mOLs are targeted in MS pathology. The inflammatory milieu within the central nervous system is considered a primary driver of demyelination in MS and impedes remyelination by promoting mOLs death while hindering the maturation and proliferation of OPC [<xref ref-type="bibr" rid="CR2">2</xref>]. Intriguingly, recent findings suggest that OPCs not only respond to inflammatory signals but also actively participate in modulating inflammation, influencing disease progression [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Our research has demonstrated that NF-&#x003ba;B activator 1 (Act1)-mediated IL-17 signaling in OPCs plays a critical role in the pathogenesis of EAE, an animal model for MS. IL-17 not only inhibits OPC maturation and promoting its apoptosis, but also induces the production of inflammatory cytokines and chemokines, thereby exacerbating neuroinflammation [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, OPCs aggregate in the perivascular regions of active MS lesions, contributing to blood-brain barrier disruption and CNS inflammation [<xref ref-type="bibr" rid="CR15">15</xref>]. Lipoprotein-related protein 1 (LRP1) in OPCs has been implicated in modulating neuroinflammation through antigen cross-presentation [<xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, studies have identified expression of genes involved in antigen processing and presentation by oligodendroglia cells in human MS tissues [<xref ref-type="bibr" rid="CR17">17</xref> and MS mouse models [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, including MHC-I and II genes. Notably, single-cell RNA sequencing of the oligodendroglia lineage during the peak of EAE in mice revealed a diverse immune profile present in both OPCs and OLs [<xref ref-type="bibr" rid="CR18">18</xref>, highlighting the potential for varied immune functions within this lineage in the context of MS [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par4">While single-cell transcriptomic analysis presents an opportunity to explore the full spectrum of oligodendroglial cells and their transcriptome phenotypes, this approach does come with certain limitations. Detecting abundant transcripts can be challenging due to the simultaneous sequencing of numerous cell types, and the process of isolating single cells through sorting may potentially alter gene expression [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Ribosome tagging (RiboTag) technology has emerged as a valuable in vivo method for studying gene expression and mRNA translation in specific cell types that are difficult and time-consuming to isolate using traditional techniques [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. This method involves using a RiboTag mouse line with a modified Rpl22-HA (hemagglutinin) allele, which can be activated by Cre recombinase. Consequently, immunoprecipitation of HA enables the purification of polysomes and associated mRNAs from the target cells, ensuring that the isolated mRNA represents actively translated proteins since only ribosome-bound RNAs are purified [<xref ref-type="bibr" rid="CR24">24</xref>]. In order to analyze the specific transcriptome of the oligodendroglial lineage in the EAE model, RiboTag mice were crossed with Oligo2-Cre transgenic mice [<xref ref-type="bibr" rid="CR25">25</xref>] to induce HA expression exclusively in OLCs. Subsequently, mRNA from the oligodendroglial lineage in the spinal cords was sequenced and subjected to bioinformatic analysis to identify cell-specific gene expression patterns.</p><p id="Par5">In this study, we identified 1,556 upregulated and 683 downregulated genes in OLCs from EAE mice. Enrichment analysis showed increased immune pathways, such as cytokine signaling, interferon responses, and antigen presentation, while downregulated genes were associated with myelination and neuron development. Notably, OLCs expressed cytokine, chemokine, and toll-like receptors. Further testing indicated that IFN-&#x003b3; signaling in OPCs exacerbates EAE pathology, likely by enhancing antigen processing, presentation, and cytokine/chemokine production, whereas IFN-&#x003b2; signaling appeared non-essential for disease progression. These findings underscore a pathogenic role for IFN-&#x003b3; signaling in OLCs during EAE-related inflammation.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Mice</title><p id="Par6">Ifngr1floxedmice [<xref ref-type="bibr" rid="CR26">26</xref>] (referred to as Ifngr1<sup>fl.</sup>, JAX 025394), Ifnar1<sup>fl.</sup> mice [<xref ref-type="bibr" rid="CR27">27</xref>(JAX 028256), Olig2-cre mice [<xref ref-type="bibr" rid="CR25">25</xref>] (JAX 025567), Pdgfra-cre<sup>ER</sup> mice [<xref ref-type="bibr" rid="CR28">28</xref>] (JAX 018280),Rpl22-HA flexed mice (refer to as RiboTag mice) [<xref ref-type="bibr" rid="CR24">24</xref>], and C57BL/6J mice (JAX 000664) were all procured from Jackson Laboratory. To induce PDGFRa expression in Pdgfra-CreER mice, tamoxifen was administered at a dose of 1&#x000a0;mg/mouse/day via intraperitoneal (i.p) injection for 5 consecutive days. The experimental mice, aged 8&#x02013;12 weeks, included both males and females and were housed in individually ventilated cages under specific pathogen-free conditions within accredited animal facilities. All animal procedures were ethically approved by the Institutional Animal Care and Use Committee of the University of Iowa.</p></sec><sec id="Sec4"><title>Induction and assessment of EAE</title><p id="Par7">The mice were immunized by subcutaneous injection in the right and left flank with 200&#x000a0;&#x000b5;g of MOG<sub>35&#x02009;&#x02212;&#x02009;55</sub> peptide emulsified in a 1:1 ratio in complete Freund&#x02019;s adjuvant (CFA) supplemented with 5&#x000a0;mg/ml Mycobacterium tuberculosis (Becton Dickinson, Franklin Lakes, NJ). Additionally, mice immunized with myelin peptides were each administered 500 ng of pertussis toxin (List Biologicals, Campbell, CA) via intraperitoneal injection on days 0 and 2. Clinical disease scores were documented daily based on the following criteria: 0 for no symptoms; 1 for tail weakness or loss of tail rigidity; 2 for mild hind limb weakness; 3 for partial hind limb paralysis; 4 for complete hind limb paralysis; and 5 for moribund status or death, as previously described [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec5"><title>Histological analysis</title><p id="Par8">The spinal cords were harvested from PBS-perfused EAE mice 25 days after EAE induction, approximately corresponding to the peak of disease severity. For paraffin sections, the spinal cords were fixed in 10% formalin, and all sections used were 10&#x000a0;&#x003bc;m thick. These paraffin sections were stained with hematoxylin and eosin (H&#x00026;E) to assess inflammation and demyelination. For frozen sections, fresh spinal cords were embedded in OCT (Tissue-Tek) and rapidly frozen in liquid nitrogen. The frozen sections, also 10&#x000a0;&#x003bc;m thick, were utilized for fluorescent staining. These sections were stained with specific antibodies: anti-CD3 (Abcam, ab16669), anti-MBP (Cell Signaling Technology, CST #788965), Anti-GFAP (DSHB, University of Iowa, # N206A/8), anti-HA (Sigma Aldrich, # H9658 or CST #3724), anti-NeuN (CST, #24307), anti-GST-&#x003c0; (ADI-MSA-102-E, Enzo Life Science), anti-NG2 (Sigma Aldrich, AB5320), or anti-Oligo 2 (Sigma Aldrich, #AB9610). The nuclei were counter-stained with DAPI. Antigen visualization was achieved through incubation with fluorescence-conjugated secondary antibodies from Molecular Probes.</p></sec><sec id="Sec6"><title>Quantitative real-time PCR (qRT-PCR)</title><p id="Par9">Real-time PCR analysis was conducted to measure gene expression levels. RNA was extracted from spinal cord tissue or cultured OPCs using TRIzol (Invitrogen) as per the manufacturer&#x02019;s instructions. The expression levels of all genes are presented as arbitrary units relative to the expression of the &#x003b2;-actin gene. Subsequently, the extracted RNA was promptly reversed transcribed into complementary DNA (cDNA). Quantitative PCR (Q-PCR) analysis was carried out using SYBR Green Real-time PCR Master Mix on a Real-Time PCR System (Applied Biosystems).</p></sec><sec id="Sec7"><title>Flow cytometry analysis</title><p id="Par10">OPCs were cultured from Ifngr1<sup>fl/fl</sup> mice, olig2-cre Ifngr1<sup>fl/fl</sup> mice, and Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice. OPCs from Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice were treated with either 1&#x000b5;M 4-hydroxytamoxifen in the last three days of culture to induce Cre expression or corn oil vehicle as a control. Subsequently, OPCs were stained with fluorescence-conjugated antibodies targeting CD140a (Biolegend, Clone APA5), in combination with either anti-IFNGR (Biolegend, Clone 2E2) or anti-IFN-AR (Biolegend, Clone MAR1-5A3) antibodies, all diluted at a 1:100 ratio when used. The stained cells were analyzed using a Cytek Aurora cytometer, and the data were further analyzed with FlowJo software.</p></sec><sec id="Sec8"><title>Primary culture of OPCs and differentiation</title><p id="Par11">The culture of OPCs was conducted following previously established protocols [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Briefly, neurospheres were prepared from E14.5 embryos obtained from timed pregnant females. The neurosphere medium consisted of DMEM/F12, B27 neuronal supplement (Invitrogen), and 10 ng/ml recombinant mouse epidermal growth factor (EGF, R&#x00026;D Systems). Floating neurospheres were passaged at a 1:3 ratio in the same medium every 3&#x02013;4 days. To obtain pure OPCs, neurospheres were dissociated after 2&#x02013;3 passages, and the dissociated cells were plated on poly-D-lysine-coated plates under the same neurosphere medium, but with 10 ng/mL fibroblast growth factor (FGF) and 10 ng/mL platelet-derived growth factor &#x003b1; (PDGF&#x003b1;) (Peprotech) instead of EGF. Following 6 days of culture, approximately 90% of cells were CD140a<sup>+</sup> confirming their identity as OPCs. The cultured OPCs were utilized for genotyping by flow cytometry as described above. For OPCs differentiation, 50ng/ml Triiodothyronine (T3) was added to the culture medium, with or without cytokines as controls. Cytokines were included at a concentration of 10 ng/mL each during differentiation. Matured oligodendrocytes were harvested two days post-differentiation for quantitative PCR (Q-PCR) and four days post-differentiation for immunofluorescent staining for myelin basic protein (MBP).</p></sec><sec id="Sec9"><title>RiboTag Immunoprecipitation</title><p id="Par12">RiboTag immunoprecipitations were performed as described previously [<xref ref-type="bibr" rid="CR24">24</xref>], with some modifications. Initially, the spinal cords from EAE mice at the onset of disease and na&#x000ef;ve control mice were homogenized using a tissue homogenizer in a supplemented homogenization buffer composed of 5% (w/v) concentration, containing 1% NP-40, 100 mM KCl, 100 mM Tris-HCl pH 7.4, and 12 mM MgCl<sub>2</sub>. This buffer was further enriched with 100 &#x000b5;g/ml cycloheximide, a protease inhibitor cocktail, 1&#x000a0;mg/ml heparin, RNase inhibitors (Promega, #N2115), and 1 mM dithiothreitol (DTT).The resulting homogenates underwent centrifugation, and the supernatant was then incubated at 4&#x000b0;C for 4 hours with 5 &#x000b5;l of anti-HA antibody to capture the HA tagged ribosomes (CST, Rb anti-HA #3724, 1:200). Subsequently, Pierce Protein A/G Magnetic Beads (Thermo Fisher, #88803) were bound to the antibody-ribosome complex through overnight incubation at 4&#x000b0;C on a rotator. The beads were then subjected to three washes with a high salt buffer comprising 300 mM KCl, 1% NP-40, 50 mM Tris-HCl pH 7.4, 12 mM MgCl<sub>2</sub>, 100 &#x000b5;g/ml cycloheximide, and 500 &#x000b5;M DTT. RNA was released from the ribosomes using 350 &#x000b5;l of RLT buffer (from Qiagen RNeasy kit) with 1% 2-mercaptoethanol. Subsequent RNA purification was performed using the RNeasy Plus Micro kit (Qiagen 74034) following the manufacturer&#x02019;s instructions, and the eluted RNA was collected in 16 &#x000b5;l of RNase-free water and stored at -80&#x000b0;C. Additionally, for each sample, 50 &#x000b5;l of homogenate (prior to the addition of anti-HA antibody) was set aside, stored at -20&#x000b0;C overnight, and purified using the RNeasy Micro kit as an &#x02018;input&#x02019; sample to determine oligodendroglial RNA enrichment. The RNA integrity number (RIN) was determined using the Agilent RNA 6000 Pico Kit (Agilent Technologies, #5067&#x02009;&#x02212;&#x02009;1513).</p></sec><sec id="Sec10"><title>RNA-Seq</title><p id="Par13">We initiated RNA sample preparations using 1&#x000a0;&#x000b5;g of RNA per sample. Libraries were crafted employing the NEBNext Ultra RNA Library Prep Kit for Illumina (NEB), following the manufacturer&#x02019;s guidelines, with index codes appended to identify sequences for each sample. Initially, mRNA was isolated from total RNA using poly(T) oligo-attached magnetic beads. Fragmentation ensued using divalent cations at elevated temperatures in NEBNext First Strand Synthesis Reaction Buffer (5x). First-strand cDNA synthesis employed a random hexamer primer and M-MuLV reverse transcriptase (RNase H). Subsequent second-strand cDNA synthesis utilized DNA polymerase I and RNase H. Remaining overhangs were converted to blunt ends via exonuclease&#x02013;polymerase activities. Following adenylation of the 3&#x02032; ends of DNA fragments, NEBNext Adaptor with a hairpin loop structure was ligated to facilitate hybridization. To preferentially select cDNA fragments around 150&#x02013;200&#x000a0;bp in length, library fragments were purified using the AMPure XP system (Beckman Coulter). Subsequently, 3&#x000a0;&#x000b5;l USER Enzyme (NEB) was applied to size-selected, adaptor-ligated cDNA at 37&#x000a0;&#x000b0;C for 15&#x000a0;min followed by 5&#x000a0;min at 95&#x000a0;&#x000b0;C before PCR. PCR employed Phusion High-Fidelity DNA polymerase, Universal PCR primers, and Index (X) Primer. Finally, PCR products were purified using the AMPure XP system, and library quality was assessed on the Agilent Bioanalyzer 2100 system. Index-coded sample clustering was executed on the Illumina NovaSeq sequencer per the manufacturer&#x02019;s instructions. Following cluster generation, libraries were sequenced on the same machine, yielding paired end reads.</p></sec><sec id="Sec11"><title>RNA-Seq data analysis</title><p id="Par14">Paired reads underwent initial processing on the University of Iowa high-performance computing cluster for sequence quality control and analysis. Adapters were initially removed and bases with a Phred score&#x02009;&#x0003c;&#x02009;20 were trimmed from both forward and reverse reads by using Metawrapread_qc module from Metawrap package (version 1.3.2) [<xref ref-type="bibr" rid="CR31">31</xref>]. The quality-controlled fastq files were then aligned to Mus_musculus.GRCm39.cdna.all.fa (downloaded May 27, 2022) retrieved from ENSEMBL for gene quantification. The resulting abundance.tsv file served as input for downstream analysis in R 4.1.2. Genes with a total count of &#x0003c;&#x02009;100 reads across all samples were filtered out, leaving a count file with 15,400 reads. This file was normalized and subjected to differential gene expression analysis using DeSeq2 v1.40.2<sup>32</sup>. Genes were considered significant if they met the criteria of a p-adjusted value&#x02009;&#x0003c;&#x02009;0.05, log2fold change&#x02009;&#x0003e;&#x02009;2, and a base mean abundance&#x02009;&#x0003e;&#x02009;20 reads. Subsequently, 2,239 genes were filtered from the differentially abundant gene list. These genes were then analyzed for functional pathways using the ShinyGO 0.80 server (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.sdstate.edu/go/">http://bioinformatics.sdstate.edu/go/</ext-link>). Four independent biological replicates in each group were analyzed, which yielded consistent results.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par15">The p-values for EAE clinical score were determined using two-way multiple-range analysis of variance (ANOVA) for multiple comparisons. For comparisons involving three groups, one-way ANOVA followed by the Bonferroni post hoc test was utilized. Other p-values were determined using the Mann-Whitney test or Students t-test. Unless specified otherwise, all results are presented as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). A p-value of &#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Specificity of oligodendroglial lineage mRNA isolation</title><p id="Par16">To purify oligodendroglial lineage-enriched mRNA, we crossed RiboTag mice with the Olig2-cre transgenic mice to get Olig2-cre Rpl22-HA<sup>fl/fl</sup> mice (refer to as Olig2-cre RiboTag mice). To validate the specific expression of the HA tag in cells of the oligodendroglial lineage, we conducted immunostaining on the spinal cord tissues from Olig2-cre RiboTag mice. We utilized anti-HA antibodies in combination with antibodies targeting GST-&#x003c0; (a mature oligodendrocyte marker), NeuN (a neuronal marker), NG2 (a OPC marker) or GFAP (an astrocyte marker). Our findings revealed that while all GST-&#x003c0;<sup>+</sup> cells were HA<sup>+</sup>, less than 5% of NeuN<sup>+</sup> neurons showed HA expression&#x02014;a proportion calculated from multiple random fields of stained sections (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A; Fig. <xref rid="MOESM1" ref-type="media">S1</xref>A). We also observed NG2 and HA containing suggesting HA expression in OPCs (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>B). In contrast, No GFAP<sup>+</sup> astrocytes exhibited HA labeling. This pattern strongly indicates the precise expression of HA within cells of the oligodendroglial lineage (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). It had been previously documented [<xref ref-type="bibr" rid="CR33">33</xref> that olig2-cre expression also occurs in motor neurons, which accounts for the observed HA expression in some neurons within the spinal cord of olig2-cre RiboTag mice. Furthermore, quantitative PCR (Q-PCR) analysis demonstrated an enrichment of oligodendrocyte-specific genes such as MBP, Plp1, and Myrf1 in spinal cord samples following HA mRNA immunoprecipitation from ribosomes of olig2-cre RiboTag mice (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). In contrast, there was a notable decrease in the expression of astrocyte-specific Gfap gene and microglial/leukocyte-specific Cd45 gene post immunoprecipitation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C), along with a reduction in neuron-specific genes like NeuN, Syn1, and Syt1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Collectively, these data support the conclusion that olig2-cre induces HA expression specifically within OLCs, although some expression may also occur in motor neurons.</p><p id="Par17">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Specificity of oligodendroglial lineage mRNA isolation. (<bold>A</bold>) Fluorescent immunostaining performed on spinal cords obtained from Oligo2-Cre RiboTag mice using specified antibodies, as indicated. Co-localization is visualized in yellow following image merge, indicated by arrows, with nuclei counterstained using DAPI. (<bold>B-D</bold>) Q-PCR analysis of transcripts expressed in oligodendrocytes (Panel B), astrocytes, microglia/leukocytes (Panel C), and neuronal cells (Panel D). Total RNA was isolated from spinal cords of na&#x000ef;ve Oligo2-Cre RiboTag mice (Input), with output representing mRNA isolated post-immunoprecipitation using anti-HA antibodies from the same group of mice. Gene enrichment or de-enrichment was compared between input and output. <italic>n</italic>&#x02009;=&#x02009;4/group. Values represent the mean&#x02009;&#x000b1;&#x02009;SEM, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. Data are from one experiment representative of two independent experiments</p></caption><graphic xlink:href="12974_2025_3463_Fig1_HTML" id="d33e453"/></fig>
</p></sec><sec id="Sec15"><title>Oligodendroglial lineage reactivity at the onset of EAE</title><p id="Par18">After confirming the specificity of RiboTag-enriched mRNA from OLCs, we proceeded to isolate mRNA from the spinal cords of both na&#x000ef;ve Olig2-cre RiboTag mice and Olig2-cre RiboTag mice at the onset of EAE, characterized by tail weakness or loss of tail rigidity. The extracted mRNA underwent bulk RNA-Seq analysis. To interpret the RNA-Seq data, we initiated multi-dimensional scaling (MDS) analysis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) and hierarchical clustering analysis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B) using ward D2 distance metrics. Both analyses distinctly segregated data from na&#x000ef;ve mice and EAE mice, indicating substantial transcriptomic changes in oligodendroglial cells during EAE pathogenesis. Differential gene expression analysis, employing a Log2 fold change cutoff of 2 and padj&#x02009;=&#x02009;0.05, revealed 1556 upregulated genes and 683 downregulated genes in OLCs from EAE mice compared to na&#x000ef;ve controls (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). To understand the biological significance of these differentially expressed genes (DEGs), we conducted gene set enrichment analysis (GSEA) utilizing the GO biological process database from the ShinyGO web server. This analysis unveiled the top 20 enriched pathways associated with upregulated genes, including innate and adaptive immune responses, cytokine production, leukocyte activation, and defense responses (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). In contrast, the top 20 enriched pathways associated with downregulated genes encompassed neuron development, neuron differentiation, cell morphogenesis, and cytoskeleton organization (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E), likely implicating neurodegeneration.</p><p id="Par19">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Oligodendroglial lineage reactivity at the onset of EAE. Spinal cords from Oligo2-Cre RiboTag EAE mice at disease onset and na&#x000ef;ve control mice were homogenized, and mRNA was isolated following immunoprecipitation with anti-HA antibodies targeting ribosomes. The purified mRNAs underwent RNA-Seq using an Illumina NovaSeq sequencer. The RNA-Seq data were analyzed as follows: (<bold>A</bold>) Multi-dimensional scaling (MDS) plot displaying RNA-Seq data from spinal cords of Oligo2-Cre RiboTag na&#x000ef;ve control mice and EAE mice at disease onset. (<bold>B</bold>) Hierarchial clustering utilizing ward D2 distance metrics, highlighting distinct clustering of the samples. (<bold>C</bold>) Identification of differentially expressed genes (DESeq2) in EAE compared to the na&#x000ef;ve group, using a Log2Fold change cutoff of 2.0 and padj&#x02009;=&#x02009;0.05. (<bold>D</bold>) Presentation of the top 20 enriched pathways for 1556 upregulated genes. (<bold>E</bold>) Top 20 enriched pathways for 683 downregulated genes, as determined by the GO biological process database from the ShinyGO web server. The heatmap illustrates differentially expressed genes categorized into: (<bold>F</bold>) Myelination and Myelin assembly. (<bold>G</bold>) Antigen processing and presentation, within the GO biological process category. <italic>n</italic>&#x02009;=&#x02009;4/group</p></caption><graphic xlink:href="12974_2025_3463_Fig2_HTML" id="d33e508"/></fig>
</p><p id="Par20">Considering previous single-cell sequencing findings that highlighted the upregulation of genes related to antigen processing and presentation in OPCs during EAE [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], we performed gene ontology (GO) analysis. This analysis confirmed a significant upregulation of antigen-presenting related genes in EAE mice, such as H2-Q10, H2-Oa, H2-K1, Cd74, H2-Ab1, H2-Eb1, Tap1, and Tap2, among others (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G). Additionally, GO analysis revealed a decrease in the expression of myelination-related genes, including Ugt8a, Myrf, and Plp1, suggesting demyelination in EAE mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F). Furthermore, in line with GSEA analysis indicating enriched cytokine production, response to cytokines, and innate immune response, we conducted GO analysis specifically focusing on cytokine receptors and toll-like receptors (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A), chemokines and chemokine receptors (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>B), IFN-&#x003b2; response genes (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>C), and IFN-&#x003b3; response genes (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>D). Interestingly, we observed a substantial upregulation of type I and type-II interferon response genes in EAE OLCs (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>E). Notably, our GO analysis confirmed the expression of known cytokine receptors like Il1r1, Ifnar1, Il4ra, and Il17ra in OLCs, validating our RiboTag RNA-Seq dataset (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A). Moreover, we identified new receptor expressions in oligodendroglial cells, such as Csf2r, Il3ra, Il13ra1, and Il18r1, among others (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A-B). a more detailed comparison of gene expression in OLCs of the spinal cord between EAE and healthy controls is provided in Supplemental Table <xref rid="MOESM2" ref-type="media">1</xref>. Overall, our RNA-Seq dataset indicates a comprehensive inflammatory signature in OLCs, suggesting their potential proinflammatory role in autoimmune encephalomyelitis.</p></sec><sec id="Sec16"><title>Validation of Ribotag RNA-Seq data via qRT-PCR</title><p id="Par21">Although the RNA-Seq data provided intriguing insights, it was imperative to validate the gene expressions in OLCs in the context of EAE. To achieve this, we utilized purified mRNA from OLCs of both Olig2-cre RiboTag na&#x000ef;ve mice and Olig2-cre RiboTag EAE mice, employing SYBR Green Real-time PCR Master Mix for qRT-PCR analysis. Initially, we confirmed that genes associated with myelination, such as Plp1, Mbp, Ugt8a, Myrf, and Olig2, exhibited a significant decrease in EAE OLCs compared to their expression levels in na&#x000ef;ve OLCs. Concurrently, the neuronal marker gene Syn1 also displayed reduced expression, indicating demyelination and degeneration in EAE mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). Furthermore, our validation revealed the upregulation of key antigen processing and presenting genes in EAE OLCs, including Citta, CD74, Nlrc5, H2-K1, Tbp1, and H2-Aa (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B), thereby supporting the hypothesis that OLCs, particularly Oligodendrocyte Progenitor Cells (OPCs), may function as antigen-presenting cells in MS/EAE [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Lastly, we confirmed the increased expression of Ifngr1 and Ifnar2 in EAE OLCs, along with elevated levels of interferon response genes such as ISG56, Ifit2, Ccl2, and Cxcl10 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C). Collectively, our Q-PCR analysis validated numerous gene expressions in EAE OLCs as observed in the RNA-Seq dataset, thus affirming the reliability of the RNA-Seq data.</p><p id="Par22">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Q-PCR validation of RiboTag RNA-Seq data. Spinal cords from Oligo2-Cre RiboTag EAE mice at disease onset and na&#x000ef;ve control mice were homogenized, and mRNA was isolated following immunoprecipitation with anti-HA antibodies targeting ribosomes. The purified mRNAs underwent Q-PCR analysis to validate RNA-Seq data from Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. (<bold>A</bold>) Demonstrates decreased expression of myelination-related genes in the EAE group, as indicated. (<bold>B</bold>) Shows upregulation of genes associated with antigen processing and presentation in the EAE group. (<bold>C</bold>) Indicates upregulation of interferon response genes in the EAE group. <italic>n</italic>&#x02009;=&#x02009;4/group. Values represent the mean&#x02009;&#x000b1;&#x02009;SEM, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. Data are from one experiment representative of two independent experiments</p></caption><graphic xlink:href="12974_2025_3463_Fig3_HTML" id="d33e601"/></fig>
</p></sec><sec id="Sec17"><title>Functional validation of RNA-Seq data in vitro</title><p id="Par23">Our analysis revealed that OLCs derived from EAE mice exhibited not only an upregulation in cytokine and chemokine production but also increased expression of many of their corresponding receptors. Previously, our group demonstrated that IL-17 targets oligodendrocyte precursor cells (OPCs) in EAE, promoting pathogenesis [<xref ref-type="bibr" rid="CR14">14</xref>]. Other studies have suggested that OLCs express CXCL19, CCL2, CCL3, IL-1&#x003b2;, and IL-6 in certain contexts [<xref ref-type="bibr" rid="CR34">34</xref>, with both CCL2 and IL-1&#x003b2; shown to enhance OPC mobilization in the cuprizone model of demyelination and remyelination [<xref ref-type="bibr" rid="CR13">13</xref>]. Type 2 immune cytokines, IL-4 and IL-13, play crucial roles in modulating immune responses, with IL-4 also known to promote oligodendrocyte differentiation [<xref ref-type="bibr" rid="CR35">35</xref>]. However, the role of IL-13 in OPC maturation remains unexplored. Notably, our data demonstrated elevated expression of Il13ra1 in OLCs from EAE mice (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A).</p><p id="Par24">IL-3, known to promote EAE development [<xref ref-type="bibr" rid="CR36">36</xref>], has been implicated in glial-peripheral immune crosstalk in multiple sclerosis. Astrocytes and T cells produce IL-3, which activates inflammatory responses in microglia and myeloid cells. Interestingly, we observed that EAE also upregulates Il3ra expression in OLCs, suggesting a possible role for IL-3 in modulating these cells (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A). Additionally, our analysis identified increased expression of Il21r in OLCs from EAE mice (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>A). IL-21, which promotes Th17 differentiation and can also be secreted by Th17 cells [<xref ref-type="bibr" rid="CR37">37</xref>], plays a critical role in EAE pathogenesis [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par25">To validate these findings, we conducted in vitro studies examining the roles of IL-3, IL-13, and IL-21 in OPC maturation and differentiation, using IL-4 as a positive control. OPCs cultured from embryonic neurospheres were differentiated with T3 in the presence or absence of these cytokines. Quantitative PCR analysis of myelination-related genes (Mbp, Plp1, Ugt8a, CNPase, Mog, and Mag) revealed that IL-4 and IL-13 significantly enhanced OPC maturation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A), while IL-3 and IL-21 inhibited this process (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B). Immunohistochemical staining of MBP protein confirmed these findings: IL-4 and IL-13 enhanced MBP expression, whereas IL-3 and IL-21 suppressed it (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C). In conclusion, we functionally validated our RNA-Seq data, uncovering novel roles for IL-3, IL-13, and IL-21 in OPC maturation. These findings expand our understanding of cytokine-mediated regulation in demyelinating diseases like multiple sclerosis.</p><p id="Par26">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Functional validation of RNA-Seq results in vitro. OPCs were induced to differentiation by adding 50ng/ml Triiodothyronine (T3) to the culture medium, without (Control) or with 10 ng/mL cytokines (IL4, IL13, IL3 or IL21). Matured oligodendrocytes were harvested two days post-differentiation for Q-PCR, or four days post-differentiation for immunofluorescent staining for myelin basic protein (MBP). (<bold>A</bold>) Q-PCR analysis of myelination-related gene expression as indicated. (<bold>B</bold>) Immunofluorescent staining for MBP (left) and MBP positive cell percentage analyzed by ImageJ (right). Data are from one experiment representative of three independent experiments, with <italic>n</italic>&#x02009;=&#x02009;3 technical repeats per group in each experiment. Values represent the mean&#x02009;&#x000b1;&#x02009;SEM, p-values were determined using Students t-test, *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></caption><graphic xlink:href="12974_2025_3463_Fig4_HTML" id="d33e674"/></fig>
</p></sec><sec id="Sec18"><title>Cell-intrinsic IFN-&#x003b3; signaling in oligodendroglial lineage promotes EAE pathogenesis</title><p id="Par27">The RNA-Seq data from OLCs revealed robust activation of interferon response genes, notably IFN-&#x003b3; and IFN-&#x003b2; response genes. This indicates a potential cell-intrinsic role of IFN-&#x003b3; and IFN-&#x003b2; signaling within the oligodendroglial lineage, which may significantly contribute to the pathogenesis of EAE. Furthermore, the upregulation of IFNGR and IFNAR in OLCs at the onset of EAE was validated through qRT-PCR, confirming the initial observations (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Although the role of IFN-&#x003b3; in the context of MS and EAE is intricate, the specific impact of cell-intrinsic IFN-&#x003b3; signaling derived from OLCs on EAE pathogenesis remains unclear. We hypothesized that IFN-&#x003b3; signaling within OLCs contributes to the exacerbation of EAE pathology.</p><p id="Par28">To test this hypothesis, we conducted crossbreeding involving Ifngr1<sup>fl/fl</sup> mice and Olig2-Cre Ifngr1<sup>fl/fl</sup> mice, resulting in the generation of Olig2-Cre Ifngr1<sup>fl/fl</sup> conditional knockout mice (referred to as IFNGR cKO) and Ifngr1<sup>fl/fl</sup> wild-type control mice (referred to as IFNGR WT). Initially, we confirmed PCR genotyping accuracy through flow cytometry analysis of IFNGR in OPCs. We cultured OPCs from embryonic pups of both Ifngr1<sup>fl/fl</sup> and Olig2-Cre Ifngr1<sup>fl/fl</sup> genotypes and stained them with OPC marker CD140a antibody and IFNGR antibody. The flow cytometry data indicated successful ablation of IFNGR in OPCs from IFNGR cKO mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A, <bold>right</bold>), whereas IFNGR expression was confirmed in IFNGR WT mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A, <bold>left</bold>). Subsequently, both IFNGR cKO mice and IFNGR WT control mice were subjected to active EAE induction via subcutaneous immunization with MOG<sub>35&#x02009;&#x02212;&#x02009;55</sub> peptides. Notably, IFNGR cKO mice exhibited significantly lower EAE clinical scores compared to WT control mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B), indicative of attenuated disease severity. This was further supported by markedly lower maximum scores and cumulative scores in IFNGR cKO mice, highlighting the reduced severity of EAE (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C). Interestingly, we did not observe significant differences in disease onset, time to peak, or disease incidence between the two groups (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C), suggesting that intrinsic IFN-&#x003b3; signaling in OLCs primarily impacts the effector stage of EAE. Consistent with the amelioration of disease severity, histopathological analysis revealed reduced accumulation of infiltrating immune cells and resultant demyelination in the spinal cord of IFNGR cKO mice compared to controls (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D). Collectively, these findings strongly suggest that OLCs-intrinsic IFN-&#x003b3; signaling plays a crucial role in promoting EAE pathogenesis.</p><p id="Par29">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Cell-intrinsic IFN-&#x003b3; induced signaling in oligodendroglial lineage promotes EAE pathogenesis. (<bold>A</bold>) Flow cytometry analysis indicates Ifngr1 deletion in OPCs cultured from Olig2-Cre Ifngr1<sup>fl/fl</sup> mice as indicated. OPCs were cultured from embryonic pups of Ifngr1<sup>fl/fl</sup> mice and Olig2-Cre Ifngr1<sup>fl/fl</sup> genotypes. (<bold>B</bold>) Mean clinical score of EAE in Ifngr1<sup>fl/fl</sup> mice and Olig2-Cre Ifngr1<sup>fl/fl</sup> mice induced by active immunization with MOG<sub>35&#x02013;55</sub> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, two-way ANOVA). (<bold>C</bold>) Disease stage-specific activities in EAE influenced by specific Ifngr1 ablation in oligodendroglial lineage cells. (<bold>D</bold>) Hematoxylin and eosin (H&#x00026;E) staining, anti-CD3 immunostaining, and myelin basic protein (MBP) staining were performed as indicated on lumbar spinal cords harvested 25 days after immunization. Data are from one experiment representative of three independent experiments, with <italic>n</italic>&#x02009;=&#x02009;5/group in each experiment. Error bars indicate SEM; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></caption><graphic xlink:href="12974_2025_3463_Fig5_HTML" id="d33e772"/></fig>
</p><p id="Par30">Notably, our analysis revealed increased CD3&#x02009;+&#x02009;T cell infiltration in the spinal cord of WT EAE mice compared to IFNGR cKO mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D). Previous studies have suggested that IFN-&#x003b3; promotes antigen processing and presentation in OPCs, enhancing antigen-specific T cell activation. Antigen-presenting cells (APCs) play a crucial role in reactivating infiltrating T cells in EAE, leading to T cell expansion and exacerbation of disease [<xref ref-type="bibr" rid="CR38">38</xref>]. Intriguingly, antigen-specific CD8&#x02009;+&#x02009;T cells have been shown to exert cytotoxic effects on OPCs in ex vivo co-culture systems and in adoptive transfer-cuprizone demyelination models, inducing OPC cell death [<xref ref-type="bibr" rid="CR39">39</xref>]. This prompted us to investigate whether ablation of IFNGR specifically in OLCs affects OPC numbers or lineage progression in the context of EAE. We stained spinal cords from IFNGR cKO and WT EAE mice with NG2 and Olig2 antibodies, which mark OPCs and OLCs, respectively. We found a significant increase in NG2&#x02009;+&#x02009;OPCs in WT EAE mice compared to IFNGR cKO EAE mice (Fig. <xref rid="MOESM1" ref-type="media">S3</xref>A). However, the total number of Olig2&#x02009;+&#x02009;OLCs in IFNGR cKO EAE mice was significantly higher than that in WT control mice, suggesting decrease of mature oligodendrocytes in WT EAE mice (Fig. <xref rid="MOESM1" ref-type="media">S3</xref>B). Together, these findings suggest that IFNGR ablation in OLCs leads to a reduction in OPCs but an increase in mature oligodendrocytes compared to WT mice in the setting of EAE.</p></sec><sec id="Sec19"><title>Cell-intrinsic IFN-&#x003b2; signaling in oligodendroglial lineage is dispensable for EAE pathogenesis</title><p id="Par31">In contrast to the complex role of IFN-&#x003b3; in the development of MS/EAE, systemic administration of IFN-&#x003b2; has emerged as the most widely used therapy for MS, offering prolonged periods of remission, reduced severity of relapses, and decreased inflammatory lesions in the CNS [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The absence of either IFN-&#x003b2; or IFNAR has been linked to a more severe and chronic form of EAE [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. However, the underlying mechanisms behind the therapeutic effects of IFN-&#x003b2; on MS/EAE remain unclear. This prompted us to investigate whether intrinsic IFN-&#x003b2; signaling in OLCs acts as a negative regulator in EAE pathogenesis.</p><p id="Par32">To address this question, we initially attempted to obtain Ifnar1<sup>fl/fl</sup> and Olig2-Cre Ifnar1<sup>fl/fl</sup> mice for EAE experiments. However, we faced challenges in acquiring <italic>Olig2-Cre Ifnar</italic><sup><italic>fl/fl</italic></sup> mice, leading us to speculate that this gene in the oligodendroglial lineage might be critical for embryonic development&#x02014;a hypothesis worth investigating in future studies. As an alternative, we utilized Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice. We verified the deletion efficiency by culturing OPCs from Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice and inducing Ifnar1 deletion through 4-OHT treatment (an active metabolite of tamoxifen) on these cells. Vehicle-treated OPCs and wild-type (WT) OPCs served as controls. Our results demonstrated over 95% deletion of Ifnar1 in 4-OHT-treated OPCs, compared to vehicle-treated OPCs and WT OPCs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A), confirming the effectiveness of the inducible Cre system in mediating Ifnar1 ablation in OPCs.</p><p id="Par33">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Cell-intrinsic IFN-&#x003b2; induced signaling in oligodendroglial lineage is dispensable EAE pathogenesis. (<bold>A</bold>) Flow cytometry analysis indicates Ifnar1 deletion in OPCs cultured from Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice after 4-Hydroxytamoxifen (4-OHT) induction as indicated. OPCs were cultured from embryonic pups of Ifngr1<sup>fl/fl</sup> mice and Pdgfra-Cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> genotypes, 1&#x000b5;M OHT was used to induce Cre expression and Ifnar1 deletion. (<bold>B</bold>) Mean clinical score of EAE in Ifnar1<sup>fl/fl</sup> mice and Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice induced by active immunization with MOG<sub>35&#x02013;55</sub> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, two-way ANOVA). (<bold>C</bold>) Disease stage-specific activities in EAE influenced by specific Ifnar1 ablation in oligodendroglial lineage cells. (<bold>D</bold>) Hematoxylin and eosin (H&#x00026;E) staining, anti-CD3 immunostaining, and myelin basic protein (MBP) staining were performed as indicated on lumbar spinal cords harvested 25 days after immunization. Data are from one experiment representative of three independent experiments, with <italic>n</italic>&#x02009;=&#x02009;5/group in each experiment. Error bars indicate SEM; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p></caption><graphic xlink:href="12974_2025_3463_Fig6_HTML" id="d33e891"/></fig>
</p><p id="Par34">Subsequently, we induced Ifnar1 deletion in OLCs of Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice in vivo using tamoxifen. The control group consisted of Ifnar1<sup>fl/fl</sup> littermate mice treated with tamoxifen. Henceforth, the tamoxifen-treated Pdgfra-cre<sup>ER</sup> Ifnar1<sup>fl/fl</sup> mice are denoted as IFN-AR cKO mice, while the tamoxifen-treated Ifnar1<sup>fl/fl</sup> mice are labeled as IFNAR WT control mice. Both groups underwent active EAE induction. Surprisingly, we did not observe a significant difference in mean EAE clinical scores between the two groups post-EAE induction (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B). Consistently, there were no discernible differences in disease onset, maximum clinical score, time to peak, cumulative clinical score, or disease incidence between the experimental groups (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C). Corresponding to the disease severity observed between the groups, histopathological analysis revealed comparable accumulation of infiltrating immune cells and resultant demyelination in the spinal cord of IFN-AR cKO mice compared to controls (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D). Consequently, we conclude that cell-intrinsic IFN-&#x003b2; signaling in OLCs is dispensable for the pathogenesis of EAE.</p></sec><sec id="Sec20"><title>Differential immune responses of OPCs to IFN-&#x003b3; and IFN-&#x003b2;</title><p id="Par35">The distinct impacts of IFN-&#x003b3; and IFN-&#x003b2; signaling within OLCs are pivotal in understanding EAE pathogenesis, prompting an exploration into their disparate effects. Oligodendrocytes treated with IFN-&#x003b3; experience apoptosis or necrosis [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. IFN-&#x003b3; can initiate death-related pathways in OPCs depending on the dose [<xref ref-type="bibr" rid="CR49">49</xref>, but it can also suppress OPC differentiation and maturation without overt death at optimal dosage [<xref ref-type="bibr" rid="CR50">50</xref>]. Notably, IFN-&#x003b3; inhibits cell cycle exit during OPC differentiation, rendering them susceptible to apoptosis and hindering their maturation [<xref ref-type="bibr" rid="CR51">51</xref>]. Conversely, IFN-&#x003b2; exerts no discernible influence on OPC proliferation, differentiation, or survival, indicating a differential impact compared to IFN-&#x003b3; [<xref ref-type="bibr" rid="CR52">52</xref>]. Given that demyelination characterizes MS/EAE, these findings partially elucidate why intrinsic IFN-&#x003b3; signaling in OLCs, as opposed to IFN-&#x003b2;, contributes to EAE pathogenesis, albeit without considering the inflammatory context of oligodendroglia in these earlier studies.</p><p id="Par36">To analyze the targeted gene expression by IFN-&#x003b3; and IFN-&#x003b2; at the onset of EAE, we conducted GO analysis specifically focusing on IFN-&#x003b3; and IFN-&#x003b2; response genes from our RiboTag RNA-seq dataset. We found a specific enrichment of IFN-&#x003b3; and IFN-&#x003b2; response immune genes in OLCs at EAE onset, revealing both shared and distinct gene expression patterns (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>C-E). To delve deeper, we conducted qRT-PCR assays in vitro to decipher how OPCs respond differentially to IFN-&#x003b3; and IFN-&#x003b2; treatments. Our findings indicate a robust response of genes related to MHC class I antigen processing and presentation (Tap1, &#x003b2;2m, and H2-D1) to IFN-&#x003b3; compared to IFN-&#x003b2; (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A). Similarly, genes linked to MHC class II antigen processing and presentation (H2-Aa, H2-Eb1, and Cd74) showed significantly higher upregulation in response to IFN-&#x003b3; (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B). Further analysis revealed a unique set of genes (Nlrc5, Citta, Ccl2, and Ccl7) that responded specifically to IFN-&#x003b3; (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C), consistent with our RNA-Seq data. Intriguingly, IFN-&#x003b2;, but not IFN-&#x003b3;, induced the expression of Irf1 and Irf7, which are critical for host defense mechanisms in OPCs (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D). These findings collectively suggest that OLCs-intrinsic IFN-&#x003b3; signaling may exacerbate EAE pathogenesis by enhancing antigen processing, presentation, and chemokine production (e.g., Ccl2 and Ccl7), while OLCs-intrinsic IFN-&#x003b2; signaling likely contributes to host defense mechanisms.</p><p id="Par37">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Differential roles of type I and type II interferons on OPC. Oligodendrocyte progenitor cells (OPCs) were cultured from embryonic pups of C57BL/6 mice, following the procedures outlined in the Material and Methods section. The OPCs were then divided into three groups: untreated, treated with 20 ng/ml IFN-&#x003b2;, or treated with 20 ng/ml IFN-&#x003b3;, respectively, for a duration of 6&#x000a0;h. Subsequently, mRNA was extracted for Q-PCR analysis. (<bold>A</bold>) Depicts the expression of MHC-I-related genes. (<bold>B</bold>) Depicts the expression of MHC-II-related genes. (<bold>C</bold>) Highlights genes specifically induced by IFN-&#x003b3;. (<bold>D</bold>) Highlights genes specifically induced by IFN-&#x003b2;. Data are from one experiment representative of three independent experiments, with <italic>n</italic>&#x02009;=&#x02009;3 technical repeats per group in each experiment. Error bars represent SEM, with ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="12974_2025_3463_Fig7_HTML" id="d33e985"/></fig>
</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par38">The RiboTag approach, which targets ribosome-associated mRNAs, provides a more accurate representation of actively translated genes, offering a clearer view of the translational state within specific cellular compartments. Thus, mRNAs isolated through the RiboTag method reflect the translatome, providing a snapshot of gene expression during active translation [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Using RiboTag RNA-Seq on EAE mice at disease onset, we identified 1,556 upregulated and 683 downregulated genes in OLCs compared to healthy controls. The upregulated genes were primarily involved in innate and adaptive immune responses, particularly cytokine production and defense responses. In contrast, downregulated genes were mainly linked to neuron development, cell morphogenesis, regulation of transport, and myelination. Among the enriched pathways, IFN-&#x003b3; and IFN-&#x003b2; responsive genes were highly represented, prompting us to investigate their OLC-intrinsic roles in EAE pathogenesis. Notably, we found a significant pathogenic role for cell-intrinsic IFN-&#x003b3; signaling in OLCs, whereas IFN-&#x003b2; signaling appeared dispensable for disease progression or suppression. These findings highlight the complex and context-dependent roles of interferons in neuroinflammation.</p><p id="Par39">The reasons for decreased myelin gene expression in EAE remains unclear. We, along with other groups, have previously stained spinal cords from EAE and normal control mice [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. These studies indicate that EAE induction increases the number of OPCs while reducing the number of mature oligodendrocytes, leading to an elevated OPC/mOLG ratio in EAE mice. Since myelination-related genes are predominantly expressed in mature oligodendrocytes, this shift could explain the observed reduction in myelin gene expression. Another contributing factor could be the inflammatory environment in the CNS of EAE mice, which may directly suppress myelin gene expression [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par40">Our study reveals a pro-inflammatory role for OLCs in EAE, suggesting their potential involvement in MS. Using RiboTag RNA-Seq, we observed a distinct transcriptional shift in OLCs during EAE, which aligns with immune modulation. Our data suggest that OLCs play an active role in neuroinflammation, in addition to their well-established function in myelination. This finding supports previous work done by the Castelo-Branco group, which demonstrated immune gene expression in both OPCs and mature oligodendrocytes in EAE mice using single-cell RNA sequencing (scRNA-Seq), and they termed these cells as inflammatory oligodendrocyte lineage cells (iOLCs) [<xref ref-type="bibr" rid="CR18">18</xref>]. They identified upregulated genes associated with antigen processing, T cell cytotoxicity, immunoglobulin secretion, cytokine production (e.g., IL-4, IL-13, IL-8), dendritic cell differentiation, and interferon response genes in both OPCs and mature oligodendrocytes [<xref ref-type="bibr" rid="CR18">18</xref>]. Our analysis supports these findings and expands upon them, identifying additional cytokines, chemokines, and their receptors, as well as various toll-like receptors in OLCs. Further comparison of our RiboTag data with single-cell data could offer insights into the methodological advantages and the specific contributions of OPCs and mature oligodendrocytes to OLC-mediated neuroinflammation in EAE.</p><p id="Par41">In this study, we primarily validated the sequencing data in OPCs, as they are easier to culture in vitro and can be identified by surface markers like NG2 and CD140a/PDGFR&#x003b1;. Future work will extend validation to mature oligodendrocytes using reporter mice. Altogether, our findings provide compelling evidence that oligodendroglial lineage cells play a significant role in EAE pathogenesis, an animal model for MS. By leveraging RiboTag technology, we were able to isolate and analyze mRNA specifically from these cells, revealing a complex and dynamic transcriptomic landscape during disease progression.</p><p id="Par42">Although Olig2 is a well-established lineage marker for oligodendrocytes, previous studies have shown that Olig2-Cre is also partially expressed in motor neurons [<xref ref-type="bibr" rid="CR33">33</xref>]. Our histology analysis similarly showed sparse HA tag expression in neurons. Interestingly, downregulated genes in our dataset were largely associated with neuron development, cell morphogenesis, transport regulation, and myelination. This raises the possibility that some downregulated genes linked to neuronal development or function may originate from neurons rather than OLCs. However, the situation appears more complex, as these pathways are also implicated in scRNA-Seq datasets from OLCs [<xref ref-type="bibr" rid="CR18">18</xref>], suggesting that OLCs share some gene expression patterns with neurons in EAE, possibly even under normal conditions. The downregulation of genes involved in neuron development and myelination supports the idea that CNS inflammation disrupts normal oligodendrocyte function, contributing to the demyelination observed in MS. Validation of these findings through qRT-PCR strengthens the reliability of the RNA-Seq data and underscores the importance of OLCs within the inflammatory environment of EAE. Future studies should further investigate these shared gene expression patterns to deepen our understanding of OLC and neuron interactions in disease and homeostasis.</p><p id="Par43">Both RiboTag RNA-Seq and scRNA-Seq data indicate an enriched response to IFN-&#x003b3; and IFN-&#x003b2; in OLCs during EAE [<xref ref-type="bibr" rid="CR18">18</xref>]. In vitro studies have demonstrated that IFN-&#x003b3; promotes antigen processing and presentation in OPCs and activates co-cultured T cells, including both CD4&#x02009;+&#x02009;and CD8&#x02009;+&#x02009;subsets [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Additionally, IFN-&#x003b3; inhibits OPC maturation and proliferation in vitro [<xref ref-type="bibr" rid="CR51">51</xref>]. However, it remains unclear whether IFN-&#x003b3; exerts any cell-intrinsic effects in OLCs that influence the pathogenesis of EAE and MS. To address this, we specifically deleted IFNGR1 in OLCs using Olig2 Cre mice and assessed the impact on EAE progression. Our data indicates that IFN-&#x003b3; signaling within OLCs contributes to the pathogenesis of EAE. The role of IFN-&#x003b3; in EAE/MS remains controversial, with studies suggesting both beneficial and pathogenic effects. While IFN-&#x003b3; administration in MS patients and EAE mice exacerbates neuroinflammation and clinical symptoms [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>], IFN-&#x003b3; and IFNGR knockout mice exhibit increased susceptibility to EAE, with heightened morbidity and mortality [<xref ref-type="bibr" rid="CR60">60</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>]. Furthermore, IFN-&#x003b3; has stage-specific effects on EAE development [<xref ref-type="bibr" rid="CR63">63</xref>]. Compounding the complexity, modulation of IFN-&#x003b3; signaling has distinct outcomes depending on the CNS cell type. For instance, silencing IFN-&#x003b3; signaling in astrocytes alleviates EAE, while its suppression in microglia exacerbates the disease [<xref ref-type="bibr" rid="CR64">64</xref>]. Our findings extend this concept to OLCs, highlighting the importance of targeted therapies in specific cellular compartments during EAE/MS.</p><p id="Par44">Notably, we observed decreased CD3&#x02009;+&#x02009;T cell infiltration in the spinal cords of Ifngr1 KO mice compared to WT controls. IFN-&#x003b3; enhances antigen processing and presentation, particularly MHC Class I, and upregulation of MHC I and antigen presentation pathways in OLCs is evident in our RiboTag RNA-Seq data. Thus, Ifngr1 KO OLCs may evade myelin antigen-specific cytotoxic T cells by failing to provide T cell recruitment chemokines and present antigens. Intriguingly, we observed a higher frequency of OLCs in Ifngr1 KO EAE mice, supporting this hypothesis. However, the results are complex, as we also observed more OPCs in WT EAE spinal cords. This contrasts with a previous report suggesting that antigen-specific CD8&#x02009;+&#x02009;cytotoxic T cells can kill OPCs in an adoptive transfer-cuprizone demyelination model [<xref ref-type="bibr" rid="CR39">39</xref>]. The reasons for this discrepancy are unclear, but we speculate that the hyper-inflammatory CNS environment in WT EAE mice may promote OPC expansion while inhibiting differentiation, outweighing the cytotoxic effects of T cells and leading to increased OPC numbers compared to Ifngr1 KO mice. Further investigation is needed to clarify the relative antigen-presenting capabilities of OPCs and mature oligodendrocytes in MS/EAE.</p><p id="Par45">While previous studies suggest that IFN-&#x003b2; does not significantly influence OPC proliferation, differentiation, or survival, indicating a differential effect compared to IFN-&#x003b3; [<xref ref-type="bibr" rid="CR52">52</xref>, our preliminary findings suggest that OPCs do respond to IFN-&#x003b2; by expressing IFN-stimulated genes. IFN-&#x003b2; is a first-line treatment for relapsing forms of MS, and the absence of either IFN-&#x003b2; or its receptor (IFNAR) has been linked to more severe and chronic forms of EAE [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Furthermore, the engagement of IFNAR on myeloid cells exacerbates EAE, leading to an enhanced effector phase and increased mortality [<xref ref-type="bibr" rid="CR65">65</xref>]. However, the cell-intrinsic role of IFN-&#x003b2; in OLCs during EAE remains unclear. Our data suggests that this intrinsic pathway may be dispensable for EAE development. Interestingly, loss of neuronal IFN-&#x003b2;-IFNAR signaling has been associated with Parkinson&#x02019;s disease-like dementia [<xref ref-type="bibr" rid="CR66">66</xref>], suggesting a protective role for IFN-&#x003b2; in neuronal homeostasis. In our study, we were unable to obtain Olig2Cre Ifnar1<sup>fl/fl</sup> pups, although Olig2Cre Ifnar1<sup>fl/+</sup> mice appeared normal, suggesting that IFN-&#x003b2;-IFNAR signaling may play a role in OLC development and warrants further investigation. In practice, distinguishing between type I and type II interferon response genes remains a challenge [<xref ref-type="bibr" rid="CR67">67</xref>]. To better understand the differential roles of OLC-intrinsic IFN-&#x003b3; and IFN-&#x003b2; signaling in EAE pathogenesis, we identified genes related to antigen processing and presentation that showed elevated expression in response to IFN-&#x003b3;. Additionally, a unique set of genes (Nlrc5, Citta, Ccl2, and Ccl7) was specifically induced by IFN-&#x003b3; in OPCs, consistent with our RNA-Seq data. In contrast, IFN-&#x003b2; induced a much higher expression of Irf1 and Irf7, both of which are critical for host defense mechanisms. Further elucidation of the distinct responses to IFN-&#x003b3; and IFN-&#x003b2; in OLCs in vivo will enhance our understanding of interferon-stimulated genes (ISGs) and their potential as therapeutic targets in MS.</p><p id="Par46">The identification of iOLCs, as previously described by the Castelo-Branco group [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], aligns with our findings, expanding on their observations by identifying additional cytokines, chemokines, and toll-like receptors. This reinforces the concept of OLCs as active participants in neuroinflammation rather than passive myelinating cells. The observed upregulation of cytokine receptors such as Il13ra1, Il3ra, and Il21r in OLCs suggests these cells actively participate in immune-mediated neuroinflammation. Notably, while IL-4 and IL-13 positively influenced OPC maturation, IL-3 and IL-21 inhibited this process, underscoring their distinct and contrasting roles in regulating myelination. These findings align with previous studies implicating IL-17 and other cytokines in EAE pathogenesis and provide new evidence for IL-13&#x02019;s potential to support OPC differentiation. Conversely, the inhibitory roles of IL-3 and IL-21 highlight their contribution to the inflammatory milieu, further linking glial-peripheral immune crosstalk to the progression of demyelinating diseases. By validating RNA-Seq predictions through functional assays, this work broadens our understanding of cytokine-mediated effects on OPCs, paving the way for targeted therapeutic strategies in conditions like multiple sclerosis. The main limitation of our study on IL-3, IL-13, and IL-21 in OPC differentiation is the lack of specificity validation. Future studies should address this by incorporating blocking antibodies and receptor gene knockdown/knockout approaches.</p><p id="Par47">In conclusion, our data establish OLCs as active contributors to immune modulation in EAE, with distinct roles for type I and type II interferons and other cytokines. These findings pave the way for exploring OLC-specific inflammatory pathways as therapeutic targets. Future work should investigate the modulation of cytokine signaling within OLCs and its impact on neuroinflammation, demyelination, and CNS repair, offering new opportunities for innovative MS treatments.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12974_2025_3463_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12974_2025_3463_MOESM2_ESM.csv"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Y.W. performed most of the experiments, prepared the figures, interpreted the data, and reviewed the manuscript. S.G. analyzed sequencing data and contributed to manuscript writing. A.M. contributed to data interpretation and manuscript revision. Z.K. was integral for experimental design, manuscript writing, data interpretation and project coordination. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Startup fund from the Department of pathology at the University of IOWA, NIH R01 NS104164, and R21AG076895 to Z.K. NIH T32AI007260 (PIs: Butler and Wu) to S.G.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval</title><p id="Par48">All animal procedures were ethically approved by the Institutional Animal Care and Use Committee of the University of Iowa.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>J</given-names></name><name><surname>da Costa</surname><given-names>NM</given-names></name><name><surname>Cheadle</surname><given-names>L</given-names></name></person-group><article-title>Emerging roles of oligodendrocyte precursor cells in neural circuit development and remodeling</article-title><source>Trends Neurosci</source><year>2023</year><volume>46</volume><issue>8</issue><fpage>628</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2023.05.007</pub-id><pub-id pub-id-type="pmid">37286422</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Buchanan J, da Costa NM, Cheadle L. Emerging roles of oligodendrocyte precursor cells in neural circuit development and remodeling. Trends Neurosci. 2023;46(8):628&#x02013;39. 10.1016/j.tins.2023.05.007. PubMed PMID: 37286422; PMCID: 10524797.<pub-id pub-id-type="pmid">37286422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Tepavcevic V, Lubetzki C. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Brain: a journal of neurology. 2022;145(12):4178&#x02013;92. 10.1093/brain/awac307. PubMed PMID: 36093726.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name><name><surname>Niu</surname><given-names>J</given-names></name></person-group><article-title>Pathological potential of oligodendrocyte precursor cells: Terra incognita</article-title><source>Trends Neurosci</source><year>2023</year><volume>46</volume><issue>7</issue><fpage>581</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2023.04.003</pub-id><pub-id pub-id-type="pmid">37183154</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Yi C, Verkhratsky A, Niu J. Pathological potential of oligodendrocyte precursor cells: Terra incognita. Trends Neurosci. 2023;46(7):581&#x02013;96. 10.1016/j.tins.2023.04.003. PubMed PMID: 37183154.<pub-id pub-id-type="pmid">37183154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Fancy</surname><given-names>SPJ</given-names></name></person-group><article-title>Mechanisms of oligodendrocyte progenitor developmental migration</article-title><source>Dev Neurobiol</source><year>2021</year><volume>81</volume><issue>8</issue><fpage>985</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1002/dneu.22856</pub-id><pub-id pub-id-type="pmid">34643996</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Xia W, Fancy SPJ. Mechanisms of oligodendrocyte progenitor developmental migration. Dev Neurobiol. 2021;81(8):985&#x02013;96. 10.1002/dneu.22856. PubMed PMID: 34643996.<pub-id pub-id-type="pmid">34643996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Castaneda</surname><given-names>A</given-names></name><name><surname>Gaultier</surname><given-names>A</given-names></name></person-group><article-title>Adult oligodendrocyte progenitor cells - Multifaceted regulators of the CNS in health and disease</article-title><source>Brain Behav Immun</source><year>2016</year><volume>57</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.01.005</pub-id><pub-id pub-id-type="pmid">26796621</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fernandez-Castaneda A, Gaultier A. Adult oligodendrocyte progenitor cells - Multifaceted regulators of the CNS in health and disease. Brain Behav Immun. 2016;57:1&#x02013;7. 10.1016/j.bbi.2016.01.005. PubMed PMID: 26796621; PMCID: 4940337.<pub-id pub-id-type="pmid">26796621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Czopka</surname><given-names>T</given-names></name></person-group><article-title>Myelination-independent functions of oligodendrocyte precursor cells in health and disease</article-title><source>Nat Neurosci</source><year>2023</year><volume>26</volume><issue>10</issue><fpage>1663</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41593-023-01423-3</pub-id><pub-id pub-id-type="pmid">37653126</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Xiao Y, Czopka T. Myelination-independent functions of oligodendrocyte precursor cells in health and disease. Nat Neurosci. 2023;26(10):1663&#x02013;9. 10.1038/s41593-023-01423-3. PubMed PMID: 37653126.<pub-id pub-id-type="pmid">37653126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Akay</surname><given-names>LA</given-names></name><name><surname>Effenberger</surname><given-names>AH</given-names></name><name><surname>Tsai</surname><given-names>LH</given-names></name></person-group><article-title>Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function</article-title><source>Genes Dev</source><year>2021</year><volume>35</volume><issue>3&#x02013;4</issue><fpage>180</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1101/gad.344218.120</pub-id><pub-id pub-id-type="pmid">33526585</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Akay LA, Effenberger AH, Tsai LH. Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function. Genes Dev. 2021;35(3&#x02013;4):180&#x02013;98. 10.1101/gad.344218.120. PubMed PMID: 33526585; PMCID: 7849363.<pub-id pub-id-type="pmid">33526585</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>P</given-names></name><name><surname>Chandraratna</surname><given-names>D</given-names></name><name><surname>Angood</surname><given-names>C</given-names></name><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>BV</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group><article-title>Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity</article-title><source>Neurology</source><year>2014</year><volume>83</volume><issue>11</issue><fpage>1022</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000768</pub-id><pub-id pub-id-type="pmid">25200713</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022&#x02013;4. 10.1212/WNL.0000000000000768. PubMed PMID: 25200713; PMCID: 4162299.<pub-id pub-id-type="pmid">25200713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jakimovski</surname><given-names>D</given-names></name><name><surname>Bittner</surname><given-names>S</given-names></name><name><surname>Zivadinov</surname><given-names>R</given-names></name><name><surname>Morrow</surname><given-names>SA</given-names></name><name><surname>Benedict</surname><given-names>RH</given-names></name><name><surname>Zipp</surname><given-names>F</given-names></name><name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name></person-group><article-title>Multiple sclerosis</article-title><source>Lancet</source><year>2024</year><volume>403</volume><issue>10422</issue><fpage>183</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01473-3</pub-id><pub-id pub-id-type="pmid">37949093</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024;403(10422):183&#x02013;202. 10.1016/S0140-6736(23)01473-3. PubMed PMID: 37949093.<pub-id pub-id-type="pmid">37949093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Jacobs BM, Peter M, Giovannoni G, Noyce AJ, Morris HR, Dobson R. Towards a global view of multiple sclerosis genetics. Nature reviews Neurology. 2022;18(10):613&#x02013;&#x02009;23. 10.1038/s41582-022-00704-y. PubMed PMID: 36075979.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>EP</given-names></name><name><surname>Bergles</surname><given-names>DE</given-names></name><name><surname>Calabresi</surname><given-names>PA</given-names></name></person-group><article-title>Immune cell modulation of oligodendrocyte lineage cells</article-title><source>Neurosci Lett</source><year>2020</year><volume>715</volume><fpage>134601</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2019.134601</pub-id><pub-id pub-id-type="pmid">31693930</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Harrington EP, Bergles DE, Calabresi PA. Immune cell modulation of oligodendrocyte lineage cells. Neurosci Lett. 2020;715:134601. 10.1016/j.neulet.2019.134601. PubMed PMID: 31693930; PMCID: 6981227.<pub-id pub-id-type="pmid">31693930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd</surname><given-names>AF</given-names></name><name><surname>Miron</surname><given-names>VE</given-names></name></person-group><article-title>The pro-remyelination properties of microglia in the central nervous system</article-title><source>Nat Reviews Neurol</source><year>2019</year><volume>15</volume><issue>8</issue><fpage>447</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0184-2</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lloyd AF, Miron VE. The pro-remyelination properties of microglia in the central nervous system. Nat Reviews Neurol. 2019;15(8):447&#x02013;58. 10.1038/s41582-019-0184-2. PubMed PMID: 31256193.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Moyon</surname><given-names>S</given-names></name><name><surname>Dubessy</surname><given-names>AL</given-names></name><name><surname>Aigrot</surname><given-names>MS</given-names></name><name><surname>Trotter</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>JK</given-names></name><name><surname>Dauphinot</surname><given-names>L</given-names></name><name><surname>Potier</surname><given-names>MC</given-names></name><name><surname>Kerninon</surname><given-names>C</given-names></name><name><surname>Melik Parsadaniantz</surname><given-names>S</given-names></name><name><surname>Franklin</surname><given-names>RJ</given-names></name><name><surname>Lubetzki</surname><given-names>C</given-names></name></person-group><article-title>Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration</article-title><source>J Neuroscience: Official J Soc Neurosci</source><year>2015</year><volume>35</volume><issue>1</issue><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0849-14.2015</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L, Potier MC, Kerninon C, Melik Parsadaniantz S, Franklin RJ, Lubetzki C. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. J Neuroscience: Official J Soc Neurosci. 2015;35(1):4&#x02013;20. PubMed PMID: 25568099; PMCID: 6605244.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zepp</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chandrasekharan</surname><given-names>U</given-names></name><name><surname>DiCorleto</surname><given-names>PE</given-names></name><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2&#x02009;+&#x02009;glial cells</article-title><source>Nat Neurosci</source><year>2013</year><volume>16</volume><issue>10</issue><fpage>1401</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nn.3505</pub-id><pub-id pub-id-type="pmid">23995070</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, Chandrasekharan U, DiCorleto PE, Trapp BD, Ransohoff RM, Li X. Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2&#x02009;+&#x02009;glial cells. Nat Neurosci. 2013;16(10):1401&#x02013;8. Epub 20130901. doi: 10.1038/nn.3505. PubMed PMID: 23995070; PMCID: PMC4106025.<pub-id pub-id-type="pmid">23995070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>J</given-names></name><name><surname>Tsai</surname><given-names>HH</given-names></name><name><surname>Hoi</surname><given-names>KK</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Fancy</surname><given-names>SPJ</given-names></name></person-group><article-title>Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering CNS inflammation</article-title><source>Nat Neurosci</source><year>2019</year><volume>22</volume><issue>5</issue><fpage>709</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0369-4</pub-id><pub-id pub-id-type="pmid">30988524</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Niu J, Tsai HH, Hoi KK, Huang N, Yu G, Kim K, Baranzini SE, Xiao L, Chan JR, Fancy SPJ. Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering CNS inflammation. Nat Neurosci. 2019;22(5):709&#x02013;18. 10.1038/s41593-019-0369-4. PubMed PMID: 30988524; PMCID: 6486410.<pub-id pub-id-type="pmid">30988524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Castaneda</surname><given-names>A</given-names></name><name><surname>Chappell</surname><given-names>MS</given-names></name><name><surname>Rosen</surname><given-names>DA</given-names></name><name><surname>Seki</surname><given-names>SM</given-names></name><name><surname>Beiter</surname><given-names>RM</given-names></name><name><surname>Johanson</surname><given-names>DM</given-names></name><name><surname>Liskey</surname><given-names>D</given-names></name><name><surname>Farber</surname><given-names>E</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Overall</surname><given-names>CC</given-names></name><name><surname>Dupree</surname><given-names>JL</given-names></name><name><surname>Gaultier</surname><given-names>A</given-names></name></person-group><article-title>The active contribution of OPCs to neuroinflammation is mediated by LRP1</article-title><source>Acta Neuropathol</source><year>2020</year><volume>139</volume><issue>2</issue><fpage>365</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-02073-1</pub-id><pub-id pub-id-type="pmid">31552482</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Fernandez-Castaneda A, Chappell MS, Rosen DA, Seki SM, Beiter RM, Johanson DM, Liskey D, Farber E, Onengut-Gumuscu S, Overall CC, Dupree JL, Gaultier A. The active contribution of OPCs to neuroinflammation is mediated by LRP1. Acta Neuropathol. 2020;139(2):365&#x02013;82. 10.1007/s00401-019-02073-1. PubMed PMID: 31552482; PMCID: 6994364.<pub-id pub-id-type="pmid">31552482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Jakel</surname><given-names>S</given-names></name><name><surname>Agirre</surname><given-names>E</given-names></name><name><surname>Mendanha Falcao</surname><given-names>A</given-names></name><name><surname>van Bruggen</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Knuesel</surname><given-names>I</given-names></name><name><surname>Malhotra</surname><given-names>D</given-names></name><name><surname>Ffrench-Constant</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name></person-group><article-title>Altered human oligodendrocyte heterogeneity in multiple sclerosis</article-title><source>Nature</source><year>2019</year><volume>566</volume><issue>7745</issue><fpage>543</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0903-2</pub-id><pub-id pub-id-type="pmid">30747918</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jakel S, Agirre E, Mendanha Falcao A, van Bruggen D, Lee KW, Knuesel I, Malhotra D, Ffrench-Constant C, Williams A, Castelo-Branco G. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566(7745):543&#x02013;7. 10.1038/s41586-019-0903-2. PubMed PMID: 30747918; PMCID: 6544546.<pub-id pub-id-type="pmid">30747918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Falcao</surname><given-names>AM</given-names></name><name><surname>van Bruggen</surname><given-names>D</given-names></name><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Meijer</surname><given-names>M</given-names></name><name><surname>Jakel</surname><given-names>S</given-names></name><name><surname>Agirre</surname><given-names>E</given-names></name><name><surname>Samudyata, Floriddia</surname><given-names>EM</given-names></name><name><surname>Vanichkina</surname><given-names>DP</given-names></name><name><surname>Ffrench-Constant</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Guerreiro-Cacais</surname><given-names>AO</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name></person-group><article-title>Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>12</issue><fpage>1837</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0236-y</pub-id><pub-id pub-id-type="pmid">30420755</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Falcao AM, van Bruggen D, Marques S, Meijer M, Jakel S, Agirre E, Samudyata, Floriddia EM, Vanichkina DP, Ffrench-Constant C, Williams A, Guerreiro-Cacais AO, Castelo-Branco G. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med. 2018;24(12):1837&#x02013;44. 10.1038/s41591-018-0236-y. Epub 20181112.<pub-id pub-id-type="pmid">30420755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Cardona</surname><given-names>JG</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Martin</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Strasburger</surname><given-names>H</given-names></name><name><surname>Herbst</surname><given-names>L</given-names></name><name><surname>Alexis</surname><given-names>M</given-names></name><name><surname>Karnell</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>T</given-names></name><name><surname>Dutta</surname><given-names>R</given-names></name><name><surname>Goverman</surname><given-names>J</given-names></name><name><surname>Bergles</surname><given-names>D</given-names></name><name><surname>Calabresi</surname><given-names>PA</given-names></name></person-group><article-title>Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>3887</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11638-3</pub-id><pub-id pub-id-type="pmid">31467299</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Kirby L, Jin J, Cardona JG, Smith MD, Martin KA, Wang J, Strasburger H, Herbst L, Alexis M, Karnell J, Davidson T, Dutta R, Goverman J, Bergles D, Calabresi PA. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat Commun. 2019;10(1):3887. 10.1038/s41467-019-11638-3. PubMed PMID: 31467299; PMCID: 6715717.<pub-id pub-id-type="pmid">31467299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">van Bruggen D, Agirre E, Castelo-Branco G. Single-cell transcriptomic analysis of oligodendrocyte lineage cells. Current opinion in neurobiology. 2017;47:168&#x02013;&#x02009;75. 10.1016/j.conb.2017.10.005. PubMed PMID: 29126015.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>E</given-names></name><name><surname>Bean</surname><given-names>JC</given-names></name><name><surname>Carey</surname><given-names>DP</given-names></name><name><surname>Quintana</surname><given-names>A</given-names></name><name><surname>McKnight</surname><given-names>GS</given-names></name></person-group><article-title>RiboTag: ribosomal tagging strategy to analyze Cell-Type-Specific mRNA expression in vivo</article-title><source>Curr Protoc Neurosci</source><year>2019</year><volume>88</volume><issue>1</issue><fpage>e77</fpage><pub-id pub-id-type="doi">10.1002/cpns.77</pub-id><pub-id pub-id-type="pmid">31216392</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sanz E, Bean JC, Carey DP, Quintana A, McKnight GS. RiboTag: ribosomal tagging strategy to analyze Cell-Type-Specific mRNA expression in vivo. Curr Protoc Neurosci. 2019;88(1):e77. 10.1002/cpns.77. PubMed PMID: 31216392; PMCID: 6615552.<pub-id pub-id-type="pmid">31216392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name><surname>Winter</surname><given-names>DR</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>Vargas Aguilar</surname><given-names>S</given-names></name><name><surname>Spinrad</surname><given-names>A</given-names></name><name><surname>Sarrazin</surname><given-names>S</given-names></name><name><surname>Ben-Yehuda</surname><given-names>H</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Zelada Gonzalez</surname><given-names>F</given-names></name><name><surname>Perrin</surname><given-names>P</given-names></name><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Gury</surname><given-names>M</given-names></name><name><surname>Lara-Astaiso</surname><given-names>D</given-names></name><name><surname>Thaiss</surname><given-names>CA</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Bahar Halpern</surname><given-names>K</given-names></name><name><surname>Baruch</surname><given-names>K</given-names></name><name><surname>Deczkowska</surname><given-names>A</given-names></name><name><surname>Lorenzo-Vivas</surname><given-names>E</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name><name><surname>Elinav</surname><given-names>E</given-names></name><name><surname>Sieweke</surname><given-names>MH</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><article-title>Microglia development follows a Stepwise program to regulate brain homeostasis</article-title><source>Science</source><year>2016</year><volume>353</volume><issue>6301</issue><fpage>aad8670</fpage><pub-id pub-id-type="doi">10.1126/science.aad8670</pub-id><pub-id pub-id-type="pmid">27338705</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, Keren-Shaul H, Gury M, Lara-Astaiso D, Thaiss CA, Cohen M, Bahar Halpern K, Baruch K, Deczkowska A, Lorenzo-Vivas E, Itzkovitz S, Elinav E, Sieweke MH, Schwartz M, Amit I. Microglia development follows a Stepwise program to regulate brain homeostasis. Science. 2016;353(6301):aad8670. 10.1126/science.aad8670. PubMed PMID: 27338705.<pub-id pub-id-type="pmid">27338705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo-Ferrer</surname><given-names>I</given-names></name><name><surname>Khakh</surname><given-names>BS</given-names></name><name><surname>Diaz-Castro</surname><given-names>B</given-names></name></person-group><article-title>Cell-specific RNA purification to study translatomes of mouse central nervous system</article-title><source>STAR Protocols</source><year>2022</year><volume>3</volume><issue>2</issue><fpage>101397</fpage><pub-id pub-id-type="doi">10.1016/j.xpro.2022.101397</pub-id><pub-id pub-id-type="pmid">35620074</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bravo-Ferrer I, Khakh BS, Diaz-Castro B. Cell-specific RNA purification to study translatomes of mouse central nervous system. STAR Protocols. 2022;3(2):101397. 10.1016/j.xpro.2022.101397. PubMed PMID: 35620074; PMCID: 9127423.<pub-id pub-id-type="pmid">35620074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>DR</given-names></name><name><surname>McKnight</surname><given-names>GS</given-names></name><name><surname>Amieux</surname><given-names>PS</given-names></name></person-group><article-title>Cell-type-specific isolation of ribosome-associated mRNA from complex tissues</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><issue>33</issue><fpage>13939</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907143106</pub-id><pub-id pub-id-type="pmid">19666516</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci USA. 2009;106(33):13939&#x02013;44. 10.1073/pnas.0907143106. PubMed PMID: 19666516; PMCID: 2728999.<pub-id pub-id-type="pmid">19666516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Zawadzka</surname><given-names>M</given-names></name><name><surname>Rivers</surname><given-names>LE</given-names></name><name><surname>Fancy</surname><given-names>SP</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Tripathi</surname><given-names>R</given-names></name><name><surname>Jamen</surname><given-names>F</given-names></name><name><surname>Young</surname><given-names>K</given-names></name><name><surname>Goncharevich</surname><given-names>A</given-names></name><name><surname>Pohl</surname><given-names>H</given-names></name><name><surname>Rizzi</surname><given-names>M</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name><name><surname>Kessaris</surname><given-names>N</given-names></name><name><surname>Suter</surname><given-names>U</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name><name><surname>Franklin</surname><given-names>RJ</given-names></name></person-group><article-title>CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination</article-title><source>Cell Stem Cell</source><year>2010</year><volume>6</volume><issue>6</issue><fpage>578</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.04.002</pub-id><pub-id pub-id-type="pmid">20569695</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Zawadzka M, Rivers LE, Fancy SP, Zhao C, Tripathi R, Jamen F, Young K, Goncharevich A, Pohl H, Rizzi M, Rowitch DH, Kessaris N, Suter U, Richardson WD, Franklin RJ. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. 2010;6(6):578&#x02013;90. PubMed PMID: 20569695; PMCID: 3856868.<pub-id pub-id-type="pmid">20569695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Carrero</surname><given-names>JA</given-names></name><name><surname>Uppaluri</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Archambault</surname><given-names>JM</given-names></name><name><surname>Lai</surname><given-names>KS</given-names></name><name><surname>Chan</surname><given-names>SR</given-names></name><name><surname>Sheehan</surname><given-names>KC</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-gamma receptor subunit 1 (IFNGR1)</article-title><source>J Immunol</source><year>2013</year><volume>191</volume><issue>8</issue><fpage>4223</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300910</pub-id><pub-id pub-id-type="pmid">24048899</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lee SH, Carrero JA, Uppaluri R, White JM, Archambault JM, Lai KS, Chan SR, Sheehan KC, Unanue ER, Schreiber RD. Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-gamma receptor subunit 1 (IFNGR1). J Immunol. 2013;191(8):4223&#x02013;34. 10.4049/jimmunol.1300910. PubMed PMID: 24048899; PMCID: 3874833.<pub-id pub-id-type="pmid">24048899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Prigge</surname><given-names>JR</given-names></name><name><surname>Hoyt</surname><given-names>TR</given-names></name><name><surname>Dobrinen</surname><given-names>E</given-names></name><name><surname>Capecchi</surname><given-names>MR</given-names></name><name><surname>Schmidt</surname><given-names>EE</given-names></name><name><surname>Meissner</surname><given-names>N</given-names></name></person-group><article-title>Type I IFNs act upon hematopoietic progenitors to protect and maintain hematopoiesis during Pneumocystis lung infection in mice</article-title><source>J Immunol</source><year>2015</year><volume>195</volume><issue>11</issue><fpage>5347</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501553</pub-id><pub-id pub-id-type="pmid">26519535</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N. Type I IFNs act upon hematopoietic progenitors to protect and maintain hematopoiesis during Pneumocystis lung infection in mice. J Immunol. 2015;195(11):5347&#x02013;57. 10.4049/jimmunol.1501553. PubMed PMID: 26519535; PMCID: 4655130.<pub-id pub-id-type="pmid">26519535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Fukaya</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Bergles</surname><given-names>DE</given-names></name></person-group><article-title>NG2&#x02009;+&#x02009;CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration</article-title><source>Neuron</source><year>2010</year><volume>68</volume><issue>4</issue><fpage>668</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.009</pub-id><pub-id pub-id-type="pmid">21092857</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2&#x02009;+&#x02009;CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron. 2010;68(4):668&#x02013;81. PubMed PMID: 21092857; PMCID: 2989827.<pub-id pub-id-type="pmid">21092857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Swaidani</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Barlow</surname><given-names>JL</given-names></name><name><surname>Gulen</surname><given-names>MF</given-names></name><name><surname>Bulek</surname><given-names>K</given-names></name><name><surname>Do</surname><given-names>JS</given-names></name><name><surname>Aronica</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>AN</given-names></name><name><surname>Min</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) innate cell population</article-title><source>Immunity</source><year>2012</year><volume>36</volume><issue>5</issue><fpage>821</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.021</pub-id><pub-id pub-id-type="pmid">22608496</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kang Z, Swaidani S, Yin W, Wang C, Barlow JL, Gulen MF, Bulek K, Do JS, Aronica M, McKenzie AN, Min B, Li X. Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) innate cell population. Immunity. 2012;36(5):821&#x02013;33. PubMed PMID: 22608496; PMCID: 3376903.<pub-id pub-id-type="pmid">22608496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Pedraza</surname><given-names>CE</given-names></name><name><surname>Monk</surname><given-names>R</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>Q</given-names></name><name><surname>Macklin</surname><given-names>WB</given-names></name></person-group><article-title>Production, characterization, and efficient transfection of highly pure oligodendrocyte precursor cultures from mouse embryonic neural progenitors</article-title><source>Glia</source><year>2008</year><volume>56</volume><issue>12</issue><fpage>1339</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/glia.20702</pub-id><pub-id pub-id-type="pmid">18512250</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Pedraza CE, Monk R, Lei J, Hao Q, Macklin WB. Production, characterization, and efficient transfection of highly pure oligodendrocyte precursor cultures from mouse embryonic neural progenitors. Glia. 2008;56(12):1339&#x02013;52. 10.1002/glia.20702. PubMed PMID: 18512250; PMCID: 4395472.<pub-id pub-id-type="pmid">18512250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="data"><name><surname>Uritskiy</surname><given-names>GV</given-names></name><name><surname>DiRuggiero</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><year>2018</year><data-title>MetaWRAP-a flexible pipeline for genome-resolved metagenomic data analysis</data-title><pub-id pub-id-type="doi">10.1186/s40168-018-0541-1</pub-id><comment>PubMed PMID: 30219103; PMCID: 6138922</comment></element-citation><mixed-citation id="mc-CR31" publication-type="data">Uritskiy GV, DiRuggiero J, Taylor J. Microbiome. 2018;6(1):158. 10.1186/s40168-018-0541-1. PubMed PMID: 30219103; PMCID: 6138922. MetaWRAP-a flexible pipeline for genome-resolved metagenomic data analysis.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><issue>12</issue><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Love MI, Huber W, Anders S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. 10.1186/s13059-014-0550-8. PubMed PMID: 25516281; PMCID: PMC4302049.<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Kessaris</surname><given-names>N</given-names></name><name><surname>Fogarty</surname><given-names>M</given-names></name><name><surname>Iannarelli</surname><given-names>P</given-names></name><name><surname>Grist</surname><given-names>M</given-names></name><name><surname>Wegner</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name></person-group><article-title>Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage</article-title><source>Nat Neurosci</source><year>2006</year><volume>9</volume><issue>2</issue><fpage>173</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nn1620</pub-id><pub-id pub-id-type="pmid">16388308</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kessaris N, Fogarty M, Iannarelli P, Grist M, Wegner M, Richardson WD. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat Neurosci. 2006;9(2):173&#x02013;9. 10.1038/nn1620. PubMed PMID: 16388308; PMCID: 6328015.<pub-id pub-id-type="pmid">16388308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>L</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name></person-group><article-title>Crossing boundaries: interplay between the immune system and oligodendrocyte lineage cells</article-title><source>Semin Cell Dev Biol</source><year>2021</year><volume>116</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2020.10.013</pub-id><pub-id pub-id-type="pmid">33162336</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kirby L, Castelo-Branco G. Crossing boundaries: interplay between the immune system and oligodendrocyte lineage cells. Semin Cell Dev Biol. 2021;116:45&#x02013;52. 10.1016/j.semcdb.2020.10.013. PubMed PMID: 33162336.<pub-id pub-id-type="pmid">33162336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Mu</surname><given-names>H</given-names></name><name><surname>Hitchens</surname><given-names>TK</given-names></name><name><surname>Foley</surname><given-names>LM</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Leak</surname><given-names>RK</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>The interleukin-4/PPARgamma signaling axis promotes oligodendrocyte differentiation and remyelination after brain injury</article-title><source>PLoS Biol</source><year>2019</year><volume>17</volume><issue>6</issue><fpage>e3000330</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000330</pub-id><pub-id pub-id-type="pmid">31226122</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhang Q, Zhu W, Xu F, Dai X, Shi L, Cai W, Mu H, Hitchens TK, Foley LM, Liu X, Yu F, Chen J, Shi Y, Leak RK, Gao Y, Chen J, Hu X. The interleukin-4/PPARgamma signaling axis promotes oligodendrocyte differentiation and remyelination after brain injury. PLoS Biol. 2019;17(6):e3000330. 10.1371/journal.pbio.3000330. PubMed PMID: 31226122; PMCID: 6608986.<pub-id pub-id-type="pmid">31226122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>K</given-names></name><name><surname>Hellerbrand</surname><given-names>S</given-names></name><name><surname>Hermann</surname><given-names>F</given-names></name><name><surname>Riedhammer</surname><given-names>C</given-names></name><name><surname>Talke</surname><given-names>Y</given-names></name><name><surname>Schiechl</surname><given-names>G</given-names></name><name><surname>Rodriguez Gomez</surname><given-names>M</given-names></name><name><surname>Kutzi</surname><given-names>S</given-names></name><name><surname>Halbritter</surname><given-names>D</given-names></name><name><surname>Goebel</surname><given-names>N</given-names></name><name><surname>Bruhl</surname><given-names>H</given-names></name><name><surname>Weissert</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name></person-group><article-title>IL-3 promotes the development of experimental autoimmune encephalitis</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><issue>16</issue><fpage>e87157</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.87157</pub-id><pub-id pub-id-type="pmid">27734026</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Renner K, Hellerbrand S, Hermann F, Riedhammer C, Talke Y, Schiechl G, Rodriguez Gomez M, Kutzi S, Halbritter D, Goebel N, Bruhl H, Weissert R, Mack M. IL-3 promotes the development of experimental autoimmune encephalitis. JCI Insight. 2016;1(16):e87157. 10.1172/jci.insight.87157. PubMed PMID: 27734026; PMCID: 5053150.<pub-id pub-id-type="pmid">27734026</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Awasthi</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>TB</given-names></name><name><surname>Oukka</surname><given-names>M</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>IL-21 initiates an alternative pathway to induce Proinflammatory T(H)17 cells</article-title><source>Nature</source><year>2007</year><volume>448</volume><issue>7152</issue><fpage>484</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature05970</pub-id><pub-id pub-id-type="pmid">17581588</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce Proinflammatory T(H)17 cells. Nature. 2007;448(7152):484&#x02013;7. 10.1038/nature05970. PubMed PMID: 17581588; PMCID: 3805028.<pub-id pub-id-type="pmid">17581588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2(9):762-4. 10.1038/ni0901-762. PubMed PMID: 11526378.</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nat Biotechnol</source><year>2016</year><volume>34</volume><issue>5</issue><fpage>525</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525&#x02013;7. 10.1038/nbt.3519. Epub 20160404.<pub-id pub-id-type="pmid">27043002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Tourbah A, Lyon-Caen O. Interferons in multiple sclerosis: ten years&#x02019; experience. Biochimie. 2007;89(6&#x02013;7):899&#x02013;902. 10.1016/j.biochi.2007.03.016. PubMed PMID: 17574320.</mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68(24 Suppl 4):S8&#x02013;11. 10.1212/01.wnl.0000277703.74115.d2. PubMed PMID: 17562848.</mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name></person-group><article-title>Multiple sclerosis and its treatment</article-title><source>J R Coll Physicians Lond</source><year>1999</year><volume>33</volume><issue>4</issue><fpage>315</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10472018</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Giovannoni G, Miller DH. Multiple sclerosis and its treatment. J R Coll Physicians Lond. 1999;33(4):315&#x02013;22. PubMed PMID: 10472018; PMCID: 9665764.<pub-id pub-id-type="pmid">10472018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Panitch HS. Early treatment trials with interferon beta in multiple sclerosis. Mult Scler. 1995;1(Suppl 1):S17&#x02013;21. PubMed PMID: 9345392.</mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Zhai</surname><given-names>Q</given-names></name></person-group><article-title>Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in Db/db mice</article-title><source>Pharmacol Res</source><year>2008</year><volume>57</volume><issue>4</issue><fpage>318</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2008.03.002</pub-id><pub-id pub-id-type="pmid">18434188</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhang F, Sun C, Wu J, He C, Ge X, Huang W, Zou Y, Chen X, Qi W, Zhai Q. Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in Db/db mice. Pharmacol Res. 2008;57(4):318&#x02013;23. PubMed PMID: 18434188.<pub-id pub-id-type="pmid">18434188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>EY</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice</article-title><source>J Clin Investig</source><year>2008</year><volume>118</volume><issue>5</issue><fpage>1680</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1172/JCI33342</pub-id><pub-id pub-id-type="pmid">18382764</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Investig. 2008;118(5):1680&#x02013;90. 10.1172/JCI33342. PubMed PMID: 18382764; PMCID: 2276397.<pub-id pub-id-type="pmid">18382764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Teige</surname><given-names>I</given-names></name><name><surname>Treschow</surname><given-names>A</given-names></name><name><surname>Teige</surname><given-names>A</given-names></name><name><surname>Mattsson</surname><given-names>R</given-names></name><name><surname>Navikas</surname><given-names>V</given-names></name><name><surname>Leanderson</surname><given-names>T</given-names></name><name><surname>Holmdahl</surname><given-names>R</given-names></name><name><surname>Issazadeh-Navikas</surname><given-names>S</given-names></name></person-group><article-title>IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><issue>9</issue><fpage>4776</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.9.4776</pub-id><pub-id pub-id-type="pmid">12707359</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, Holmdahl R, Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol. 2003;170(9):4776&#x02013;84. 10.4049/jimmunol.170.9.4776. PubMed PMID: 12707359.<pub-id pub-id-type="pmid">12707359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Baerwald KD, Popko B. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. Journal of neuroscience research. 1998;52(2):230-9. doi: 10.1002/(SICI)1097-4547(19980415)52:2&#x0003c;230::AID-JNR11&#x0003e;3.0.CO;2-B. PubMed PMID: 9579413.</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Vartanian</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis</article-title><source>Mol Med</source><year>1995</year><volume>1</volume><issue>7</issue><fpage>732</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/BF03401888</pub-id><pub-id pub-id-type="pmid">8612196</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Vartanian T, Li Y, Zhao M, Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med. 1995;1(7):732&#x02013;43. PubMed PMID: 8612196; PMCID: 2230017.<pub-id pub-id-type="pmid">8612196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Andrews T, Zhang P, Bhat NR. TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. Journal of neuroscience research. 1998;54(5):574&#x02013;&#x02009;83. doi: 10.1002/(SICI)1097-4547(19981201)54:5&#x0003c;574::AID-JNR2&#x0003e;3.0.CO;2-0. PubMed PMID: 9843148.</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Agresti C, D&#x02019;Urso D, Levi G. Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. The European journal of neuroscience. 1996;8(6):1106-16. 10.1111/j.1460-9568.1996.tb01278.x. PubMed PMID: 8752580.</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>DC</given-names></name><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Mayer-Proschel</surname><given-names>M</given-names></name></person-group><article-title>Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-gamma</article-title><source>J Neuroscience: Official J Soc Neurosci</source><year>2011</year><volume>31</volume><issue>16</issue><fpage>6235</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5905-10.2011</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Tanner DC, Cherry JD, Mayer-Proschel M. Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-gamma. J Neuroscience: Official J Soc Neurosci. 2011;31(16):6235&#x02013;46. 10.1523/JNEUROSCI.5905-10.2011. PubMed PMID: 21508246; PMCID: 3104669.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Heine S, Ebnet J, Maysami S, Stangel M. Effects of interferon-beta on oligodendroglial cells. Journal of neuroimmunology. 2006;177(1&#x02013;2):173&#x02013;&#x02009;80. 10.1016/j.jneuroim.2006.04.016. PubMed PMID: 16753226.</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Haimon</surname><given-names>Z</given-names></name><name><surname>Volaski</surname><given-names>A</given-names></name><name><surname>Orthgiess</surname><given-names>J</given-names></name><name><surname>Boura-Halfon</surname><given-names>S</given-names></name><name><surname>Varol</surname><given-names>D</given-names></name><name><surname>Shemer</surname><given-names>A</given-names></name><name><surname>Yona</surname><given-names>S</given-names></name><name><surname>Zuckerman</surname><given-names>B</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Chappell-Maor</surname><given-names>L</given-names></name><name><surname>Bechmann</surname><given-names>I</given-names></name><name><surname>Gericke</surname><given-names>M</given-names></name><name><surname>Ulitsky</surname><given-names>I</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><article-title>Re-evaluating microglia expression profiles using ribotag and cell isolation strategies</article-title><source>Nat Immunol</source><year>2018</year><volume>19</volume><issue>6</issue><fpage>636</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0110-6</pub-id><pub-id pub-id-type="pmid">29777220</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Haimon Z, Volaski A, Orthgiess J, Boura-Halfon S, Varol D, Shemer A, Yona S, Zuckerman B, David E, Chappell-Maor L, Bechmann I, Gericke M, Ulitsky I, Jung S. Re-evaluating microglia expression profiles using ribotag and cell isolation strategies. Nat Immunol. 2018;19(6):636&#x02013;44. 10.1038/s41590-018-0110-6. PubMed PMID: 29777220; PMCID: 5986066.<pub-id pub-id-type="pmid">29777220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>JC</given-names></name><name><surname>Thompson</surname><given-names>KK</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Tsirka</surname><given-names>SE</given-names></name></person-group><article-title>Csf1R Inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery</article-title><source>Exp Neurol</source><year>2018</year><volume>307</volume><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2018.05.021</pub-id><pub-id pub-id-type="pmid">29803827</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Nissen JC, Thompson KK, West BL, Tsirka SE. Csf1R Inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. Exp Neurol. 2018;307:24&#x02013;36. 10.1016/j.expneurol.2018.05.021. Epub 20180524.<pub-id pub-id-type="pmid">29803827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>ZG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Shang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Elias</surname><given-names>SB</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name></person-group><article-title>Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis</article-title><source>Neurobiol Dis</source><year>2015</year><volume>76</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.01.006</pub-id><pub-id pub-id-type="pmid">25680941</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zhang J, Zhang ZG, Li Y, Ding X, Shang X, Lu M, Elias SB, Chopp M. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis. 2015;76:57&#x02013;66. 10.1016/j.nbd.2015.01.006. Epub 20150211.<pub-id pub-id-type="pmid">25680941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>CJ</given-names></name><name><surname>Martin</surname><given-names>BN</given-names></name><name><surname>Bulek</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Bian</surname><given-names>G</given-names></name><name><surname>Carman</surname><given-names>JA</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dongre</surname><given-names>A</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Hambardzumyan</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>T</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>IL-17 induced NOTCH1 activation in oligodendrocyte progenitor cells enhances proliferation and inflammatory gene expression</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>15508</fpage><pub-id pub-id-type="doi">10.1038/ncomms15508</pub-id><pub-id pub-id-type="pmid">28561022</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wang C, Zhang CJ, Martin BN, Bulek K, Kang Z, Zhao J, Bian G, Carman JA, Gao J, Dongre A, Xue H, Miller SD, Qian Y, Hambardzumyan D, Hamilton T, Ransohoff RM, Li X. IL-17 induced NOTCH1 activation in oligodendrocyte progenitor cells enhances proliferation and inflammatory gene expression. Nat Commun. 2017;8:15508. 10.1038/ncomms15508. Epub 20170531.<pub-id pub-id-type="pmid">28561022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Newman</surname><given-names>TA</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Weller</surname><given-names>RO</given-names></name></person-group><article-title>Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis</article-title><source>Neuropathol Appl Neurobiol</source><year>2004</year><volume>30</volume><issue>4</issue><fpage>374</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2003.00546</pub-id><pub-id pub-id-type="pmid">15305983</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Sun D, Newman TA, Perry VH, Weller RO. Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis. Neuropathol Appl Neurobiol. 2004;30(4):374&#x02013;84. 10.1111/j.1365-2990.2003.00546..x. PubMed PMID: 15305983.<pub-id pub-id-type="pmid">15305983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Renno</surname><given-names>T</given-names></name><name><surname>Taupin</surname><given-names>V</given-names></name><name><surname>Bourbonniere</surname><given-names>L</given-names></name><name><surname>Verge</surname><given-names>G</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>De Simone</surname><given-names>R</given-names></name><name><surname>Krakowski</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>A</given-names></name><name><surname>Owens</surname><given-names>T</given-names></name></person-group><article-title>Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE</article-title><source>Mol Cell Neurosci</source><year>1998</year><volume>12</volume><issue>6</issue><fpage>376</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1006/mcne.1998.0725</pub-id><pub-id pub-id-type="pmid">9888990</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Renno T, Taupin V, Bourbonniere L, Verge G, Tran E, De Simone R, Krakowski M, Rodriguez M, Peterson A, Owens T. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci. 1998;12(6):376&#x02013;89. 10.1006/mcne.1998.0725. PubMed PMID: 9888990.<pub-id pub-id-type="pmid">9888990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Panitch</surname><given-names>HS</given-names></name><name><surname>Hirsch</surname><given-names>RL</given-names></name><name><surname>Schindler</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>KP</given-names></name></person-group><article-title>Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system</article-title><source>Neurology</source><year>1987</year><volume>37</volume><issue>7</issue><fpage>1097</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1212/wnl.37.7.1097</pub-id><pub-id pub-id-type="pmid">3110648</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37(7):1097&#x02013;102. 10.1212/wnl.37.7.1097. PubMed PMID: 3110648.<pub-id pub-id-type="pmid">3110648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Willenborg</surname><given-names>DO</given-names></name><name><surname>Fordham</surname><given-names>S</given-names></name><name><surname>Bernard</surname><given-names>CC</given-names></name><name><surname>Cowden</surname><given-names>WB</given-names></name><name><surname>Ramshaw</surname><given-names>IA</given-names></name></person-group><article-title>IFN-gamma plays a critical down-regulatory role in the induction and effector phase of Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><issue>8</issue><fpage>3223</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.157.8.3223</pub-id><pub-id pub-id-type="pmid">8871615</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157(8):3223&#x02013;7. PubMed PMID: 8871615.<pub-id pub-id-type="pmid">8871615</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Krakowski</surname><given-names>M</given-names></name><name><surname>Owens</surname><given-names>T</given-names></name></person-group><article-title>Interferon-gamma confers resistance to experimental allergic encephalomyelitis</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><issue>7</issue><fpage>1641</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/eji.1830260735</pub-id><pub-id pub-id-type="pmid">8766573</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol. 1996;26(7):1641&#x02013;6. 10.1002/eji.1830260735. PubMed PMID: 8766573.<pub-id pub-id-type="pmid">8766573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferber</surname><given-names>IA</given-names></name><name><surname>Brocke</surname><given-names>S</given-names></name><name><surname>Taylor-Edwards</surname><given-names>C</given-names></name><name><surname>Ridgway</surname><given-names>W</given-names></name><name><surname>Dinisco</surname><given-names>C</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><name><surname>Dalton</surname><given-names>D</given-names></name><name><surname>Fathman</surname><given-names>CG</given-names></name></person-group><article-title>Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)</article-title><source>J Immunol</source><year>1996</year><volume>156</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.156.1.5</pub-id><pub-id pub-id-type="pmid">8598493</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156(1):5&#x02013;7. PubMed PMID: 8598493.<pub-id pub-id-type="pmid">8598493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Naves</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Cashman</surname><given-names>KS</given-names></name><name><surname>Rowse</surname><given-names>AL</given-names></name><name><surname>Axtell</surname><given-names>RC</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><name><surname>Mountz</surname><given-names>JD</given-names></name><name><surname>Steele</surname><given-names>C</given-names></name><name><surname>De Sarno</surname><given-names>P</given-names></name><name><surname>Raman</surname><given-names>C</given-names></name></person-group><article-title>The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>2013</year><volume>191</volume><issue>6</issue><fpage>2967</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300419</pub-id><pub-id pub-id-type="pmid">23960239</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Naves R, Singh SP, Cashman KS, Rowse AL, Axtell RC, Steinman L, Mountz JD, Steele C, De Sarno P, Raman C. The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2013;191(6):2967&#x02013;77. 10.4049/jimmunol.1300419. PubMed PMID: 23960239; PMCID: 3779698.<pub-id pub-id-type="pmid">23960239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Ciric</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lovett-Racke</surname><given-names>AE</given-names></name><name><surname>Zhang</surname><given-names>GX</given-names></name><name><surname>Rostami</surname><given-names>A</given-names></name></person-group><article-title>Silencing IFN-gamma binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><issue>9</issue><fpage>4251</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303321</pub-id><pub-id pub-id-type="pmid">25795755</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Ding X, Yan Y, Li X, Li K, Ciric B, Yang J, Zhang Y, Wu S, Xu H, Chen W, Lovett-Racke AE, Zhang GX, Rostami A. Silencing IFN-gamma binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity. J Immunol. 2015;194(9):4251&#x02013;64. 10.4049/jimmunol.1303321. PubMed PMID: 25795755; PMCID: 4402255.<pub-id pub-id-type="pmid">25795755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Knobeloch</surname><given-names>KP</given-names></name><name><surname>Hanisch</surname><given-names>UK</given-names></name><name><surname>Raasch</surname><given-names>J</given-names></name><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Detje</surname><given-names>C</given-names></name><name><surname>Gutcher</surname><given-names>I</given-names></name><name><surname>Mages</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name><name><surname>Bruck</surname><given-names>W</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name></person-group><article-title>Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system</article-title><source>Immunity</source><year>2008</year><volume>28</volume><issue>5</issue><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.011</pub-id><pub-id pub-id-type="pmid">18424188</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Bruck W, Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 2008;28(5):675&#x02013;86. 10.1016/j.immuni.2008.03.011. PubMed PMID: 18424188.<pub-id pub-id-type="pmid">18424188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Ejlerskov</surname><given-names>P</given-names></name><name><surname>Hultberg</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Carlsson</surname><given-names>R</given-names></name><name><surname>Ambjorn</surname><given-names>M</given-names></name><name><surname>Kuss</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Porcu</surname><given-names>G</given-names></name><name><surname>Kolkova</surname><given-names>K</given-names></name><name><surname>Friis Rundsten</surname><given-names>C</given-names></name><name><surname>Ruscher</surname><given-names>K</given-names></name><name><surname>Pakkenberg</surname><given-names>B</given-names></name><name><surname>Goldmann</surname><given-names>T</given-names></name><name><surname>Loreth</surname><given-names>D</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Issazadeh-Navikas</surname><given-names>S</given-names></name></person-group><article-title>Lack of neuronal IFN-beta-IFNAR causes lewy Body- and Parkinson&#x02019;s Disease-like dementia</article-title><source>Cell</source><year>2015</year><volume>163</volume><issue>2</issue><fpage>324</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.069</pub-id><pub-id pub-id-type="pmid">26451483</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjorn M, Kuss M, Liu Y, Porcu G, Kolkova K, Friis Rundsten C, Ruscher K, Pakkenberg B, Goldmann T, Loreth D, Prinz M, Rubinsztein DC, Issazadeh-Navikas S. Lack of neuronal IFN-beta-IFNAR causes lewy Body- and Parkinson&#x02019;s Disease-like dementia. Cell. 2015;163(2):324&#x02013;39. PubMed PMID: 26451483; PMCID: 4601085.<pub-id pub-id-type="pmid">26451483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrat</surname><given-names>FJ</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><article-title>Interferon target-gene expression and epigenomic signatures in health and disease</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><issue>12</issue><fpage>1574</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0466-2</pub-id><pub-id pub-id-type="pmid">31745335</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20(12):1574&#x02013;83. 10.1038/s41590-019-0466-2. PubMed PMID: 31745335; PMCID: 7024546.<pub-id pub-id-type="pmid">31745335</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>